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Lacher, Sarah E., Ph.D. Summer 2013     
 Toxicology 
 
P-glycoprotein Transport in Pesticide Pharmacokinetics and Toxicity: 
Investigating a Link to Parkinson’s Disease Risk 
 
Chairperson: Erica L. Woodahl 
  
  Variation in the gene that encodes P-glycoprotein (P-gp), ABCB1, has been associated 
with Parkinson’s disease risk. The aim of my research was to evaluate P-gp transport of 
pesticides that have been associated with Parkinson’s disease as a mechanism for the 
pharmacogenomic association. To facilitate this aim, a combination of models was 
utilized to determine P-gp transport of the pesticides diazinon, dieldrin, endosulfan, 
maneb, MPP+, paraquat, and rotenone.  
 
  Paraquat pharmacokinetics and brain accumulation were measured in both FVB wild-
type and mdr1a(-/-)/1b(-/-) mice. P-gp deficient mice displayed no changes in paraquat 
brain accumulation, indicating that P-gp does not mediate paraquat disposition. I 
confirmed this observation in vitro using ATPase activity, cytotoxic sensitivity, 
transepithelial transport, and rhodamine-123 inhibition assays, in which I observed no 
interaction between P-gp and paraquat. There has been recent controversy regarding 
paraquat induction of Parkinson’s disease in mice. I evaluated paraquat toxicity in both 
C57BL/6J and FVB wild-type mice. I observed no differences in any of the neurological 
endpoints in C57BL/6J and FVB mice.  
 
  I next evaluated diazinon, dieldrin, endosulfan, maneb, MPP+, and rotenone as P-gp 
substrates or inhibitors. None of the pesticides inhibited P-gp. Only rotenone stimulated 
ATPase activity, suggesting that rotenone is a P-gp substrate. It is possible that exposure 
to rotenone may confer differential Parkinson’s disease risk in individuals with genetic 
variation in ABCB1. 
 
  Collectively, I screened the pesticides associated with Parkinson’s disease as P-gp 
substrates and inhibitors. Indentifying rotenone as a P-gp substrate has provided the first 
piece of evidence towards identifying a potential mechanism for the association between 
genetic variation in ABCB1 and Parkinson’s disease. The observations gathered from the 
models of P-gp transport and pesticide toxicity evaluated herein will be pivotal in further 
evaluation of the association of genetic variation in ABCB1 and Parkinson’s disease risk. 
It is possible that this association may be a result of another exposure or endogenous 
molecule, however, the role of genetic variation in ABCB1 and Parkinson’s disease 
remains unclear. Further, the use of paraquat as a reproducible method to induce 
Parkinson’s disease in mice is an unreliable model of Parkinson’s disease and requires 
further investigation.  
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CHAPTER 1 
 
 
INTRODUCTION 
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The distribution of nutrients, toxins, and drugs to the brain is strictly regulated. In 
order to maintain homeostasis in the brain, the central nervous system (CNS) has evolved 
effective mechanisms to simultaneously protect the brain from circulating agents and 
supplies the brain with vital nutrients. Even slight perturbation of the homeostatic 
mechanisms present at the brain can lead to disease. Although altered access to the brain 
alone does not account for the source of all brain disease, it is clear that deeper 
understanding of these protective mechanisms will largely influence brain disease 
prevention, diagnosis, and treatment (Daneman, 2012).  
The brain is protected from circulating xenobiotics by an anatomic barrier, first 
described by German microbiologist Paul Ehrlich in 1885. Following injection of the 
hydrophilic dye trypan blue in rodents, Erlich observed that almost all tissues were 
stained except the brain. Alternatively, when the dye was injected directly into the brain, 
the dye stained the brain, however, the dye did not distribute to peripheral tissues. This 
observation clearly demonstrated the existence of a barrier between the blood and brain, 
now referred to as the blood-brain-barrier (BBB). While many drugs and toxicants are 
unable to cross the BBB and distribute to the brain, the BBB is not an absolute barrier to 
systemically circulating xenobiotics 
The BBB contains multiple mechanisms that protect and regulate access to the 
brain. The BBB is comprised of capillaries in which endothelial cells form tight junctions 
with adjacent cells. The tight junctions provide strong contact between the cells, 
preventing paracellular transport and distribution of polar substances to the brain (Liu et 
al., 2012). Thus molecules that do gain access to the brain must be small and lipophilic in 
order to traverse through the endothelial cells via transcellular pathways. In addition, 
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transport proteins in the cell membranes of the endothelial cells mediate the efflux or 
influx of molecules across the BBB. Carrier-mediated transport mechanisms at the BBB 
facilitate the directional flux of xenobiotics across the endothelial cells. Thus, in addition 
to the physical barrier posed by the endothelial cells, the BBB contains many transport 
mechanisms that protect the brain from the toxic effects of circulating xenobiotics. 
 The Human Genome Project identified more than 400 membrane transporters 
primarily belong to either the solute carrier (SLC) or ATP-binding cassette (ABC) 
transporter superfamilies. SLC transporters can operate as bidirectional transporters, and 
the energy for the transport is supplied by a concentration or ion gradient. Thus these 
transporters are considered passive facilitated transporters. Conversely, ABC transporters 
operate as unidirectional transporters, and the energy required for transport is provided as 
ATP. Therefore, ABC transporters are considered active facilitated transporters. SLC and 
ABC transporters are expressed in many tissues including the BBB and mediate the 
uptake of important nutrients as well as the efflux of potentially dangerous xenobiotics. 
SLC transporters transport a variety of xenobiotics including organic anions, 
organic cations, nucleotides, and amino acids. SLC transporters are commonly referred to 
as organic anion transporters (OAT) and organic cation transporters (OCT). SLC 
transporters have been shown to mediate nutrient and drug uptake at the BBB (Asaba et 
al., 2000; Gao et al., 2000; Kakyo et al., 1999). Upon consideration of the substrates of 
SLC transporters, it is clear that their main role at the BBB is to mediate the uptake of 
nutrients and xenobiotics.  
Contrary to SLC transporters, ABC transporters efflux compounds out of the cell. 
In humans there are seven ABC gene subfamilies. The gene ABCB1 (or MDR1) encodes 
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the most clinically relevant drug transporter, P-glycoprotein (P-gp). P-gp mediates the 
efflux xenobiotics in healthy tissues throughout the body including the intestine, liver, 
kidney, and at the BBB (Lin and Yamazaki, 2003a; Lin and Yamazaki, 2003b; Schinkel, 
1997; Sharom, 2006; Sharom, 2011). P-gp plays an important role in the 
pharmacokinetics and disposition of drugs from many therapeutic classes [as reviewed in 
(Cascorbi, 2011; Giacomini, 1997; Giacomini et al., 2010; Sharom, 2011)]; however, 
there is less evidence for the role of P-gp in toxicant disposition.  
Altered P-gp expression and activity have been associated with a number of 
exposure related diseases, including Parkinson’s disease, childhood acute lymphoblastic 
leukemia, renal cancer, multiple myeloma, irritable bowl syndrome, Alzheimer’s disease, 
progressive supranuclear palsy, and multiple system atrophy (Bartels et al., 2008b; 
Bartels et al., 2008a; Blokzijl et al., 2007; Drozdzik et al., 2003; Dutheil et al., 2010; 
Furuno et al., 2002; Jamroziak et al., 2004; Kuhnke et al., 2007; Le Couteur et al., 2001; 
Lee et al., 2004; Lee and Bendayan, 2004; Maggini et al., 2008; Semsei et al., 2008; 
Siegsmund et al., 2002; Tan et al., 2005; Tan et al., 2004; Urayama et al., 2007; van 
Assema et al., 2012; Vautier and Fernandez, 2009; Westerlund et al., 2009; Westerlund et 
al., 2008).  One hypothesis of the association between P-gp and Parkinson’s disease is 
that decreased P-gp transport of neurotoxicants at the BBB may lead to increased brain 
exposure and increased risk of Parkinson’s disease (Bonnet and Houeto, 1999; Caudle et 
al., 2012a; Caudle et al., 2012b; Gatto et al., 2009; Langston et al., 1984; Semchuk et al., 
1992; Steece-Collier et al., 2002). Pesticide manufacture, application, and exposure have 
been extensively associated with an increased risk to Parkinson’s disease, however, 
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Parkinson’s disease-associated neurotoxicants such as pesticides have not been evaluated 
as P-gp substrates. 
The goals of this research were to evaluate P-gp transport of the pesticides 
associated with Parkinson’s disease and investigate the link between genetic variation in 
ABCB1 and Parkinson’s disease. If P-gp transport at the BBB limits pesticide brain 
exposure, then genetic variation in ABCB1 could alter the pesticide brain concentrations 
and potential Parkinson’s disease risk. Identifying whether pesticides are P-gp substrates 
could provide a mechanism to explain the observed epidemiological association between 
genetic variation in ABCB1 and Parkinson’s disease. 
In the following sections, background information regarding the role of P-gp in 
xenobiotic disposition will be presented, as well as a thorough description of the 
protective mechanisms present at the BBB. Next, information regarding Parkinson’s 
disease phenotypes and risks will be discussed with an emphasis on the risk posed by 
pesticide exposure. Finally, current research regarding the role of ABCB1 genetic 
variation in Parkinson’s disease risk will be addressed. This introductory chapter will 
conclude with gaps in the understanding of P-gp transport of Parkinson’s disease 
associated-pesticides, and the specific aims of this research.  
 
1.1 ATP BINDING CASSETTE SUPERFAMILY: FROM DRUG TO TOXIN 
TRANSPORT   
Multiple influx and efflux transporters are expressed at the BBB to supply 
nutrients to the brain and protect it from circulating toxicants. These transport 
mechanisms include passive facilitated (energy independent) in which molecules move 
 
	  
6	  
	  
down a concentration gradient or active (energy dependent) in which transporters utilize 
energy to facilitate the movement of a molecule against its concentration gradient. The 
majority of carrier-mediated transporters involved in xenobiotic efflux utilize ATP and 
possess an ATP-binding domain.   
The ATP-binding cassette (ABC) transporter superfamily is the largest family of 
membrane transporters. ABC transporters are responsible for actively transporting a wide 
variety of compounds across cell membranes including but not limited to phospholipids, 
ions, peptides, steroids, polysaccharides, amino acids, organic anions, bile salts, drugs, 
and toxins. In humans ABC genes are organized into seven subfamilies (ABCA, ABCB, 
ABCC, ABCD, ABCE, ABCF, and ABCG) (Klein et al., 1999). Of the seven families, the 
ABCB, ABCC, and ABCG subfamilies are the most clinically relevant ABC transporters. 
The protein products of these genes are expressed in tissues important for the processes 
of absorption (intestine) and elimination (liver and kidney), and are also responsible for 
maintaining the regulatory function of blood-tissue barriers such as the BBB, blood-testes 
barrier, and placental-barrier. A summary of the three most clinically relevant ABC 
families can be found in (Table 1.1., page 25).  
ABC transporters possess nucleotide-binding domains (NBD) that bind and 
hydrolyze ATP to move substances against their concentration gradient. ABC 
transporters also contain multiple transmembrane domains that are involved in substrate 
recognition. ABC transporters are highly expressed at the BBB (Figure 1.1., page 27) 
where they prevent passage of xenobiotics across the capillary membrane into the brain 
(Begley, 2004; Dauchy et al., 2008; de Boer et al., 2003; Fricker and Miller, 2004; 
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Loscher and Potschka, 2005; Miller, 2010). The first identified and best studied ABC 
transporter, P-gp, is encoded by the gene ABCB1. 
 
1.1.1 DISCOVERY AND CHARACTERIZATION OF P-GLYCOPROTEIN 
The presence of P-gp was first discovered in drug-resistant Chinese hamster ovary 
cells (Juliano and Ling, 1976). Studies demonstrated that selecting cells in the presence 
of the chemotherapy agent colchicine resulted in clonal cell lines with pleiotropic cross-
resistance to chemically unrelated drugs (Ling, 1975; Ling and Thompson, 1974). This 
observation led to the conclusion that some currently unidentified mechanism was 
responsible for the reduced accumulation of drugs within cancer cells, thus rendering 
them resistant to chemotherapy drugs. Following isolation of the plasma membrane of 
these resistant clonal cells, a protein band was recognized at 170 kDa with intensity 
proportional to the level of drug resistance (Riordan and Ling, 1979). In 1986, the full-
length multidrug resistant gene 1 (MDR1) was cloned and was found to be homologous to 
bacterial ATP-dependent transporters (Gros et al., 1986; Ueda et al., 1986).  Since then, 
MDR1 has become commonly referred to as ABCB1, the name assigned to it following 
the ABC superfamily nomenclature.  
 
1.1.2 P-GLYCOPROTEIN: BEYOND MUTLIDRUG RESISTANCE 
Since its discovery in cancer cells, P-gp is expressed in healthy tissues throughout 
the body including the intestine, liver, kidney, and at the BBB where it mediates the 
efflux of a variety of structurally diverse xenobiotics (Lin and Yamazaki, 2003a; Lin and 
Yamazaki, 2003b; Schinkel, 1997; Sharom, 2006; Sharom, 2011). Localization of P-gp 
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expression suggests that P-gp has evolved to protect the body from xenobiotic exposure 
by effluxing these compounds into the intestinal lumen, bile, urine, and by preventing 
accumulation in the brain and other sensitive tissues. Thus, P-gp plays a major role in the 
pharmacokinetic processes of absorption, distribution, metabolism, and excretion [as 
reviewed in (Lin and Yamazaki, 2003b)].  
Translated as a single 1280 amino acid polypeptide, P-gp is made up of two semi 
homologous halves, each of which contains six transmembrane domains and an ATP- 
binding domain (Gottesman and Pastan, 1993).  Mutagenesis and antibody mapping 
studies suggest that the two halves of P-gp interact together to form a single functional 
unit (Loo and Clarke, 1994; Muller et al., 1996).  In addition, studies have demonstrated 
that P-gp extrudes its substrates directly from the cell membrane prior to entering the 
cytoplasm (Higgins and Gottesman, 1992; Homolya et al., 1993; Rosenberg et al., 1997; 
Shapiro and Ling, 1997). Although crystal structures of a bacterial ABC transporter had 
been published, it was not until 2009 that a crystal structure of mammalian P-gp (murine- 
87% sequence identity to human) was published (Aller et al., 2009).  
One of the most fascinating characteristics of P-gp is that it is able to recognize 
and transport numerous drugs with a large variety of chemical structures and therapeutic 
uses. Though there are exceptions, the majority of drugs transported by P-gp are neutral 
and basic.  One unifying feature is that the majority of P-gp substrates are lipophilic, 
supporting that partitioning into the lipid cell membrane is the first step towards efflux 
via P-gp.  Although much is known regarding the role the P-gp plays in drug distribution, 
little is known regarding toxicant substrates of P-gp. 
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1.2 THE BLOOD-BRAIN-BARRIER IN HEALTH AND DISEASE 
Neuronal homeostasis is essential for the maintenance of normal brain function. 
The structure responsible for maintaining homeostasis and protecting the brain from 
neurotoxic compounds is the BBB. Since the discovery of the BBB over 100 years ago 
most neuroscientists are familiar with the idea that the BBB has evolved as a mechanism 
to allow vital nutrients into the brain and keep neurotoxic substances out. Therefore, it is 
important to address the unique properties of the endothelial cells comprising the BBB as 
well as the contribution of drug transporters in brain penetration of xenobiotics.  
 
1.2.1 THE BIOLOGY OF THE BLOOD-BRAIN-BARRIER 
The three-cell model of the BBB is depicted in Figure 1.1., (page 27) where the 
endothelial cells of the BBB are closely connected to two other cell types, pericytes and 
astrocytes. The endothelial cells are polarized, form tight and therefore and express 
differential protein profiles on either the luminal (apical – blood facing) and abluminal 
(basolateral - brain facing) membranes. Pericytes are phagocytic cells, and in isolated 
brain capillaries there is estimated to be one pericyte for every three endothelial cells 
(Cancilla et al., 1972). The astrocytes contain foot processes that comprise the large 
majority of the capillary basement membrane. Analysis of the intimate relationship of 
astrocyte foot processes and endothelial cells clearly showed astrocyte foot processes 
forming rosette-like structures at the abluminal surface of the endothelium.  In this same 
evaluation, each astrocyte was found to send processes to a single endothelial cell, 
although one endothelial cell may receive input from multiple astrocytes (Kacem et al., 
1998). Astrocytes and pericytes are responsible for physically reinforcing the endothelial 
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cell-to-cell junctions, as well as producing factors that induce the endothelial cells’ ability 
to generate tight junction proteins (Arthur et al., 1987; Janzer and Raff, 1987). Thus, the 
function of the endothelial cells of the brain capillaries is further supported by the 
relationship with pericytes and astrocyte foot processes.  
The tight junctions that form between adjacent endothelial cells at the BBB are 
the most complex tight junctions of the entire vascular system (Claude, 1978). High 
electrical resistance (1500-2000 Ohm cm2) and low permeability are features of stable 
tight junction morphology in vivo. Several tight junction-associated proteins have been 
identified in endothelial cells including occludin, claudin-1 and -2, ZO-1 and -2, Zo-
3/p130, 7H6, and cingulin (Kniesel and Wolburg, 2000). Collectively the BBB forms and 
maintains a strict barrier to the brain that prevents polar or large molecules from gaining 
access and having potential neurotoxic effects. 
 
1.2.2 DISTRIBUTION ACROSS THE BLOOD-BRAIN-BARRIER 
Many factors contribute to the distribution of a xenobiotic to the brain. The 
pharmacokinetic processes of absorption, distribution, metabolism, and elimination all 
determine the amount of xenobiotic available for uptake and transport at the BBB.  For 
highly permeable xenobiotics, blood flow is a limiting factor, whereas other xenobiotics 
are limited by their permeability. In addition, plasma protein binding determines the 
unbound fraction of xenobiotics, thus influencing the amount of available xenobiotic 
available that is free to penetrate the BBB. Xenobiotic metabolism can occur at the BBB 
(Decleves et al., 2011), as some drug-metabolizing enzymes are present in the brain 
capillaries, although at significantly lower levels than in the liver. The endothelial cells of 
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the BBB are critical for the uptake and efflux of both endogenous and exogenous 
compounds by preventing passive hydrophilic diffusion and by expressing an array of 
transport mechanisms (Figure 1.1., page 27) (de Boer et al., 2003). 
 
1.2.3 P-GLYCOPROTEIN: PROTECTION AT THE BLOOD-BRAIN-BARRIER 
P-gp has been shown to play an important role in protecting the brain from 
circulating drugs and neurotoxicants. In humans, ABCB1 is the sole gene that encodes for 
P-gp, while in mice there are two genes, mdr1a and mdr1b. Important evidence for the 
role of P-gp at the BBB was initially obtained through studies with mdr1a knock-out 
mice;  mdr1a  is the primary P-gp isoform detected in the brain vasculature in mice. 
Following exposure to ivermectin, researchers reported that they “serendipitously” 
discovered that the mdr1a deficient animals were much more sensitive to the neurotoxic 
effects (100-fold) and had increased brain uptake (88-fold) of ivermectin than the wild-
type (Schinkel et al., 1994). Since this discovery, many reports have described the role of 
P-gp in brain distribution of therapeutics and many attempts are being made to modulate 
P-gp activity at the BBB to increase delivery of drugs to the CNS (Miller et al., 2008). 
Little is known, however, about the role that P-gp plays in brain exposure of toxicants 
and subsequent risk of neurodegenerative diseases. 
It is well established that exposure to environmental toxicants can result in 
neurodegenerative diseases. Exposure to environmental agents combined with genetic 
pre-disposition and aging, increases the risk for developing CNS diseases such as 
Parkinson’s disease, Alzheimer’s disease, and Creutzfeldt-Jakob Disease (Drozdzik et al., 
2003; Hartz et al., 2010; Hoffmeyer et al., 2000; Kortekaas et al., 2005; Vogelgesang et 
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al., 2006; Wolf et al., 2012). Decreased P-gp function at the apical membrane of the BBB 
could potentially  increase the risk of neurological disease as a result of increased 
exposure to exogenous and/or endogenous toxins.  However mechanistic knowledge in 
each of these diseases is greatly lacking to determine the main risk factors for 
neurodegenerative diseases (Bartels et al., 2009). 
 
1.3 CHARACTERISTICS AND RISK FACTORS OF PARKINSON’S DISEASE 
Parkinson’s disease is an incurable degenerative disorder of the central nervous 
system that results in crippling motor dysfunction. The pathology of Parkinson’s disease 
results from progressive loss of the dopaminergic neurons in the substantia nigra pars 
compacta (SNpc), a loss of dopamine input to the striatum, the presence of cytoplasmic 
alpha-synuclein protein aggregates known as Lewy Bodies, depigmentation of the locus 
ceruleus, and sympathetic denervation of the heart (Bennett et al., 1999; Goldstein, 2007; 
Olanow and Tatton, 1999). In addition, it has been shown that Parkinson’s disease 
patients exhibit systemic inhibition of mitochondrial complex I, which results in 
depletion of ATP and generation of toxic reactive oxygen species (Schapira et al., 1989). 
The cause of the dopaminergic cell death is unknown, but it is thought that both genetic 
and environmental factors may contribute. Some common risk factors for developing 
Parkinson’s disease are aging, genetic predisposition, and exposure to toxicants such as 
heavy metals (manganese and iron), industrial solvents, and pesticides.  
The National Institute for Neurological Disorders and Stroke (NINDS) estimated 
that 50,000 new cases of Parkinson’s disease are diagnosed in the US each year, and the 
total number of cases in the US is at least 500,000. However the total number of 
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Parkinson’s disease cases is difficult to assess, as the disease is not diagnosable until it is 
far advanced.  The prevalence of Parkinson’s disease is expected to double by 2030 
(Dorsey et al., 2007). In addition, the NINDS estimates that the economic cost of 
Parkinson’s disease in the US currently exceeds $6 billion per year. Little is known about 
Parkinson’s disease prevention and early diagnosis. Current treatment options offer 
temporary reduction of symptoms; however, these often result in devastating side effects 
such as increased involuntary movements (dyskinesia), hallucinations, impaired memory, 
and compulsive behavior. Thus, further research regarding risk factors of exposure 
related Parkinson’s disease is of obvious interest. 
 
1.3.1 EXPOSURE AND PARKINSON’S DISEASE RISK: MPTP 
The contribution of environmental exposure to the development of Parkinson’s 
disease was strongly supported after the discovery of a group of intravenous drug users 
who injected a synthetic analog of demerol that was unknowingly contaminated with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et al., 1983).  This 
exposure resulted in an acute and permanent parkinsonian state that was temporarily 
responsive to the dopamine replacement therapy, levodopa. Upon gaining access to the 
brain, MPTP is converted to 1-methyl-4-phenyl-4-phenylpyridinium ion (MPP+, 
cyperquat). MPP+ displays neurotoxicity in the SNpc and results in many parkinsonian 
pathological characteristics (Langston et al., 1984). In addition, it has been shown that 
MPP+ interacts with mitochondrial complex I and generates harmful reactive oxygen 
species (Richardson et al., 2005). These observations prompted researchers to identify 
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compounds in the environment that could be similar to MPTP, and upon exposure could 
lead to the development of Parkinson’s disease.  
 
1.3.2 EXPOSURE AND PARKINSON’S DISEASE RISK: PESTICIDES 
Pesticides are compounds designed to deter or kill insects and plants. Five billion 
pounds of pesticides were used worldwide from 2006-2007 (Grube et al., 2011). Pesticide 
exposures have not only been associated with an increased risk for developing 
Parkinson’s disease in epidemiological studies, but are also capable of inducing 
neurotoxicity such as increased dopaminergic neurodegeneration in the brain, oxidative 
stress, and loss of dopaminergic neurons in the substantia nigra in murine models of 
Parkinson’s disease. The most commonly associated pesticides associated with 
Parkinson’s disease are paraquat, rotenone, and maneb.  Although pesticides are a very 
structurally and functionally complex class of chemicals (Figure 1. 2., page 28), 
epidemiological and laboratory evidence implicate only a subset of these pesticides in 
Parkinson’s disease pathology [as reviewed in (Hatcher et al., 2008)].  These include the 
pesticides diazinon, dieldrin, endosulfan, maneb, MPP+, paraquat, and rotenone.  
 
1.3.2.1 PARAQUAT 
The herbicide paraquat is the most thoroughly evaluated pesticide as a 
parkinsonian neurotoxicant.  Paraquat was first produced in 1961 and quickly gained 
attention as a toxicant due to cases of toxicity in human exposure. It was also noted that 
paraquat is chemically homologous to the known parkinsonian neurotoxicant MPP+ 
(Figure 1.3., page 29). These observations led to the prediction that paraquat was toxic to 
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dopaminergic neurons in a similar manner as MPP+ (Dawson and Dawson, 2003; Snyder 
and D'Amato, 1985).  Paraquat exposure has been associated with an increased 
Parkinson’s disease risk in epidemiological studies (Hertzman et al., 1990; Liou et al., 
1997; Semchuk et al., 1992). Despite these epidemiological observations, it was initially 
suggested that paraquat was not a likely candidate for inducing Parkinson’s disease due 
to its polar charge, limited absorption, and poor BBB penetration (Koller, 1986). 
However, more recent studies have reported that paraquat is able to cross the BBB 
possibly through a neutral amino acid transporter, and may accumulate in the brain of 
mice (Prasad et al., 2009; Prasad et al., 2007; Shimizu et al., 2001). 
In addition to the epidemiological evidence that paraquat exposure results in 
increased Parkinson’s disease risk, it has been demonstrated in vitro that paraquat is a 
likely Parkinson’s disease inducing neurotoxicant. Paraquat (PQ2+) accepts an electron 
from a reductant during glycolysis and forms paraquat monocation (PQ+•). This quickly 
reacts with O2 to form a superoxide radical (O2•-), which then regenerates PQ2+ (Choi et 
al., 2006). The formation of the superoxide radical initiates the generation of other 
reactive oxygen species, and this is likely the main cause of paraquat toxicity. 
Mitochondrial complex I and III have both been suggested to be directly involved in the 
generation of paraquat reactive oxygen species (Castello et al., 2007; Cocheme and 
Murphy, 2008). 
The ability of paraquat to induce Parkinson’s disease in animals has recently 
become a topic of controversy. Some groups have been successful in demonstrating that 
chronic administration of paraquat leads to dopaminergic dysfunction, while others have 
argued that paraquat is not a dopaminergic neurotoxicant.  For example, chronic paraquat 
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administration has been shown to result in a 20-30% selective dopamine neuronal loss in 
the SNpc and increased expression and aggregation of alpha-synuclein (Manning-Bog et 
al., 2002; McCormack et al., 2002). To further this observation, it was shown that over-
expression of either wild-type or mutant alpha-synuclein is protective against paraquat 
toxicity (Manning-Bog et al., 2003). Finally, others have reported that paraquat exposure 
in mice leads to loss of dopaminergic neurons in the SNpc, degeneration of striatal 
terminals, and decreased locomotor activity (Brooks et al., 1999; Ossowska et al., 2006). 
In combination these reports support the ability of paraquat exposure to result in a loss of 
dopaminergic neurons.  
However, there is a growing body of contradictory evidence that suggests that 
paraquat is not able to induce Parkinson’s disease phenotypes in mice (Breckenridge et 
al., 2013; McCormack et al., 2002; McIntosh et al., 2010; Miller, 2007; Widdowson et 
al., 1996; Woolley et al., 1989). For example, in the striatum of C57BL/6J mice, the 
concentrations of dopamine, dopamine metabolites, and the rate of dopamine turnover 
have been reported to be either unaffected or only marginally affected following paraquat 
exposure (Breckenridge et al., 2013; McCormack et al., 2002; Woolley et al., 1989). 
Locomotor activity assays have also shown conflicting results following paraquat 
administration, again ranging from unaffected to marginally affected (Shepherd et al., 
2006; Yang et al., 2007). In addition, a recent report showed that paraquat-induced 
dopamine loss in the SNpc is highly dependent on genetic background. Researchers 
found that C57BL/6J, but not Swiss-Webster, mice are susceptible to dopaminergic 
toxicity following chronic paraquat administration (Jiao et al., 2012).  Further adding to 
the controversy, the Office of Research Integrity of the United States Department of 
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Health and Human Services announced on June 28, 2012 that a paper regarding chronic 
paraquat toxicity in C57BL/6J mice had been retracted due to “intentional fabrication of 
stereological cell count data” (Thiruchelvam et al., 2005). This event has further clouded 
the field of paraquat and Parkinson’s disease toxicity, and warrants further investigation 
of paraquat as a dopaminergic neurotoxicant.  
 
1.3.2.2  ROTENONE 
The second most commonly associated pesticide with Parkinson’s disease is 
rotenone. Rotenone is very lipophilic and easily crosses plasma membranes without the 
need for an uptake transporter. Initial evaluation of rotenone exposure found minimal 
SNpc damage (Ferrante et al., 1997; Thiffault et al., 2000). Other studies showed that 
rotenone administration resulted in parkinsonian symptoms including selective 
dopaminergic degeneration and cytoplasmic inclusions similar to Lewy Bodies (Betarbet 
et al., 2000). Much like MPP+, rotenone interacts with mitochondrial complex I and 
generates harmful reactive oxygen species throughout the entire brain, however, cell 
toxicity was only observed in the SNpc (Richardson et al., 2005). In addition, rotenone 
exposure has been shown to lead to increased oxidative stress, inflammation, ubiquitin 
accumulation, and proteasomal inhibition (Kim and Joh, 2006; Liu et al., 2003; Sherer et 
al., 2002; Wang et al., 2006), all of which are pathological features of Parkinson’s 
disease.  
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1.3.2.3 MANEB 
Exposure to the manganese containing pesticide, maneb, has also been implicated 
as a Parkinson’s disease risk factor. It is possible that the association between maneb 
exposure and Parkinson’s disease is due to the manganese metal core and leads to 
symptoms similar to those seen in manganism (Meco et al., 1994). Manganism is a 
neurological disease with many similar disease phenotypes as seen in Parkinson’s 
disease. One study has suggested that maneb produces reactive oxygen species via 
mitochondrial complex III (Zhang et al., 2003). Additionally, maneb has shown to 
exacerbate toxicity of other agents in mouse models, such as paraquat (Thiruchelvam et 
al., 2000a; Thiruchelvam et al., 2000b), although these publications come from the 
researcher disbarred for data fabrication, thus the interpretation of these data are difficult.  
 
1.3.2.4 ORGANOCHLORINES AND ORGANOPHOSPHATES 
Organochlorine pesticides are a class of chlorinated pesticides that have been 
banned in the United States for decades, however, they are persistent in the environment 
and are resistant to degradation.  The association of organochlorines with Parkinson’s 
disease risk is driven by several studies in dopaminergic cell lines. These studies have 
shown the ability of the organochlorines endosulfan or dieldrin to generate reactive 
oxygen species due to interaction with mitochondrial complex III, induction of ubiquitin-
proteasome dysfunction, promotion of alpha-synuclein aggregation, depletion of 
intracellular dopamine, and activation of caspases (Jia and Misra, 2007b; Kanthasamy et 
al., 2005; Kitazawa et al., 2003; Sun et al., 2005). Exposure to endosulfan or dieldrin in 
mice has been shown to reproduce many of the phenotypes seen in Parkinson’s disease 
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such as increased alpha-synuclein expression and dopaminergic dysfunction (Hatcher et 
al., 2007; Jia and Misra, 2007a). Finally, studies have demonstrated increased levels of 
dieldrin in the post-mortem brain tissue of Parkinson’s disease patients (Fleming et al., 
1994). 
Organophosphate pesticides are known neurotoxicants that inhibit 
acetylcholinesterase. Organophosphates have been evaluated as Parkinson’s disease risk 
factors and although there are case reports of people who develop severe parkinsonism 
following organophosphate exposure (Bhatt et al., 1999). While the symptoms of 
organophosphate exposure are reversible, they are not responsive to levodopa, which are 
not features of Parkinson’s disease.  It is possible that the effects of organophosphate 
exposure involves disturbance of the balance between dopaminergic and 
acetylcholinergic systems rather than specific death of the dopaminergic neurons in the 
SNpc (Hatcher et al., 2008). Diazinon is one organophosphate in particular that has been 
shown to contribute to Parkinson’s disease risk in a gene-environment interaction study 
(Slotkin and Seidler, 2011). 
 
1.4 A ROLE FOR ABCB1 PHARMACOGENOMICS IN PARKINSON’S DISEASE 
The ABCB1 gene is large and complex spanning more than 200 kb on human 
chromosome 7. The ABCB1 gene is made up of 28 exons that give rise to a 3.8 kb coding 
region. It has become evident that P-gp expression and activity is at least in part 
influenced by genetic polymorphisms in the ABCB1 gene, referred to as single nucleotide 
polymorphisms (SNPs) (Hitzl et al., 2001; Hoffmeyer et al., 2000; Kim et al., 2001). The 
four most studied functional ABCB1 SNPs are 1199G>A, 1236C>T, 2677G>T/A, and 
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3435C>T.  The 1236C>T and 3435C>T SNPs are synonymous and do not alter amino 
acid sequence. The mechanism by which these synonymous gene variants alter P-gp 
expression is unknown, although a possible effect could be altered mRNA stability or 
delayed protein translation (Kimchi-Sarfaty et al., 2007; Wang et al., 2005; Wang and 
Sadee, 2006).  
The non-synonymous SNPs 1199G>A and 2677G>T/A code for a serine to 
asparagine change at amino acid 400 and the triallelic change from an alanine to a serine 
or an alanine to a threonine change at amino acid 893, respectively (Woodahl et al., 
2009b; Woodahl and Ho, 2004; Woodahl et al., 2004; Woodahl et al., 2005). One issue in 
interpreting data regarding ABCB1 SNPs and P-gp expression and activity is that most 
studies have focused on evaluating individual SNPs and not haplotypes. Haplotypes are a 
combination of alleles in a gene that are in linkage disequilibrium and are inherited 
together. For example, most studies have investigated the role of 3435C>T on P-gp 
expression and function without accounting for the strong linkage disequilibrium with 
1236C>T, and 2677G>T/A (Woodahl and Ho, 2004). The strong linkage disequilibrium 
between ABCB1 SNPs is well known (Chowbay et al., 2003; Furuno et al., 2002; 
Horinouchi et al., 2002; Illmer et al., 2002; Johne et al., 2002; Kroetz et al., 2003; 
Siddiqui et al., 2003; Tanabe et al., 2001; Zheng et al., 2002), yet many evaluations have 
failed to account for the linkage in their study design.  
In addition to altered P-gp transport, ABCB1 genetic variation has also been 
associated with a number of neurological diseases in addition to Parkinson’s disease 
including Alzheimer’s disease, epilepsy, stroke, and HIV-associated dementia. It is 
possible that ABCB1 genetic variation causes alterations in P-gp expression and/or 
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function at the BBB, and thus alters neurotoxicant transport and distribution in the brain. 
Therefore, alterations in P-gp expression and transport due to ABCB1 genetic variation 
could be an important predictor of disease.  
 
1.4.1 ABCB1 PHARMACOGENOMICS IN PARKINSON’S DISEASE RISK 
Epidemiologic studies have found an association between ABCB1 
pharmacogenomics and susceptibility to Parkinson’s disease (Bartels et al., 2008a; 
Drozdzik et al., 2003; Dutheil et al., 2010; Furuno et al., 2002; Le Couteur et al., 2001; 
Lee et al., 2004; Lee and Bendayan, 2004; Tan et al., 2005; Tan et al., 2004; Vautier and 
Fernandez, 2009; Westerlund et al., 2009; Westerlund et al., 2008). A table summarizing 
the epidemiological associations of ABCB1 SNPs and Parkinson’s disease risk can be 
found in Table 1.2. (page 26) Studies in Asian patients showed that the 2677T/3435T or 
1236T/2677T/3435T haplotypes were significantly associated with a reduced risk of 
Parkinson’s disease (Lee et al., 2004; Tan et al., 2005). In European populations, the 
1236C>T and 3435C>T SNPs have been shown to have an increased frequency in 
Parkinson’s disease patients, while another study evaluating the 2677G>T/A and 
3435C>T SNPs found no association between allele frequencies and Parkinson’s disease 
(Furuno et al., 2002; Tan et al., 2004) Finally, a recent study in Europeans observed an 
association between ABCB1 variation and Parkinson’s disease risk, but only after 
including occupational exposure to organochlorine pesticides in the analysis; the 
researchers observed a higher risk of Parkinson’s disease in patients with 2677TT or TA 
genotypes who were also exposed to organochlorines (Dutheil et al., 2010). Although the 
authors did not report what specific organochlorine was responsible for this association, a 
 
	  
22	  
	  
personal contact with the corresponding author suggested that dieldrin is the 
organochlorine that is commonly used in the area of the population evaluated. One 
possible mechanism to explain this association may be that certain ABCB1 genetic 
variants decrease P-gp activity at the blood-brain-barrier, leading to increased brain 
accumulation of neurotoxicants and an increased incidence of Parkinson’s disease. 
 
1.4.2 BRAIN DISTRIBUTION OF VERAPAMIL IN PARKINSON’S DISEASE 
PATIENTS 
In addition to the pharmacogenetic evidence of an association between P-gp and 
Parkinson’s disease, other work has attempted to understand the role of P-gp in 
Parkinson’s disease neuropathology using the radiolabeled P-gp substrate verapamil. 
Global 11C-verapamil distribution was compared in Parkinson’s disease patients and 
healthy volunteers in imaging studies using positron emission tomography. Because 11C-
verapamil is actively transported out of the brain by P-gp, the brain distribution volume 
of 11C-verapamil is inversely related to P-gp activity at the BBB (Bart et al., 2003; 
Lubberink et al., 2007). These studies demonstrated a 20% increased brain accumulation 
of verapamil in Parkinson’s disease patients compared to control subjects, indicating that 
P-gp activity at the BBB was decreased (Bartels et al., 2008a; Kortekaas et al., 2005). 
This finding strongly suggests P-gp activity at the BBB is reduced in patients with 
Parkinson’s disease, but whether it is due to ABCB1 pharmacogenomics or mechanisms 
of down-regulation is unclear. 
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1.4.3 P-GLYCOPROTEIN TRANSPORT OF PESTICIDES 
Some studies have evaluated pesticides as substrates of P-gp (Bain and LeBlanc, 
1996; Bircsak et al., 2012; Lecoeur et al., 2006; Pivcevic and Zaja, 2006). Specifically, 
the organochlorine endosulfan has been shown to be both a P-gp substrate and inhibitor 
(Bircsak et al., 2012; Shabbir et al., 2005). The organophosphate diazinon is transported 
by P-gp in Caco-2 cells and has been shown to induce P-gp expression in rats (Lecoeur et 
al., 2006).  In another rat model, paraquat-induced lung toxicity was reduced by induction 
of P-gp with dexamethasone, while verapamil increased paraquat accumulation and 
toxicity in the lung (Dinis-Oliveira et al., 2006a; Dinis-Oliveira et al., 2006c). If 
pesticides are P-gp substrates, decreased P-gp activity at the BBB due to genetic variation 
in ABCB1 would be expected to lead to increased brain accumulation of pesticides and an 
increased risk of Parkinson’s disease. 
 
1.5 SPECIFIC AIMS 
The objectives of this research were to test the hypothesis that decreased P-gp 
transport at the BBB, due to genetic variation in ABCB1, results in an increase in brain 
accumulation of neurotoxicants and may be a risk factor for Parkinson’s disease. Using a 
combination of in vitro and in vivo models, this research aimed to identify a potential 
mechanism for the role of P-gp in Parkinson’s disease by evaluating P-gp mediated 
transport of pesticides. In Specific Aim 1, a pharmacokinetic analysis of plasma and brain 
samples following single oral doses of paraquat in FVB wild-type and FVB mdr1a(-/-)/1b(-
/-) mice was performed. Additionally, in Specific Aim 1, paraquat was evaluated as a P-gp 
substrate using in vitro models of transport. In Specific Aim 2, rotenone, maneb, 
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endosulfan, diazinon, dieldrin, and ivermectin were evaluated as potential P-gp substrates 
or inhibitors. Finally, in Specific Aim 3, C57Bl/6J and FVB wild-type mice were 
chronically exposed to paraquat, following which dopamine loss, oxidative stress, and 
motor dysfunction were evaluated. 
The following chapters detail the experimental design and research results 
completed to accomplish the goals of the research. In combination, the models chosen 
allowed for a complete and comprehensive analysis of pesticides as potential P-gp 
substrates. Understanding mechanisms of pesticide penetration at the BBB and 
accumulation in the CNS as well as which pesticides are substrates of P-gp will allow us 
to move closer to a therapy or preventative mechanism for Parkinson’s disease. 
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Table 1.1. Clinically Relevant ABC Transporters 
 
Gene Protein Tissue Substrate Inhibitor Inducer 
ABCB1 P-gp, 
MDR1 
intestine, 
liver, 
kidney, 
BBB, 
placenta, 
adrenal, 
testes 
colchicine, 
cyclosporine, 
digoxin, 
doxorubicin, 
fexofenadine, 
HIV protease 
inhibitors, 
ivermectin, 
paclitaxel, 
verapamil, 
vincristine, 
cyclosporine, 
erythromycin, 
HIV protease 
inhibitors, 
GF120918 
(elacridar), 
ketoconazole, 
LY335979, 
PSC 833 
(valspodar), 
verapamil, 
quinidine 
dexamethasone, 
grapefruit juice, 
rifampin, 
St. John’s wort 
ABCB4 MDR3 liver digoxin, 
paclitaxel, 
vinblastine 
  
ABCC1 MRP1 intestine, 
liver, 
kidney, 
BBB 
adefovir, 
indinavir 
  
ABCC2 MRP2 intestine, 
liver, 
kidney, 
BBB 
indinavir, 
cisplatin 
probenecid  
ABCC3 MRP3 intestine, 
liver, 
kidney, 
BBB 
etoposide, 
methotrexate, 
tenoposide 
  
ABCG2 BCRP intestine, 
liver,  
breast 
cancer, 
placenta 
danorubicin, 
doxorubicin, 
topotecan, 
rosuvastatin, 
sulfasalazine 
GF120918 
(elacridar) 
 
Table adapted from the U.S. FDA Drug Development and Drug Interactions website and 
the University of Washington Drug Interaction Database 
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Table 1.2. Genetic Variation in ABCB1 and Risk of Parkinson’s Disease 
 
ABCB1 SNPs 
 
Population Evaluated 
 
 
1236C>T 
 
2677G>T/A 
 
3435C>T 
Parkinson’s 
Disease Risk 
European (Furuno et al., 2002) ✓  ✓  
European (Tan et al., 2004)  ✓ ✓  
Asian (Lee et al., 2004)  ✓ ✓  
Asian (Tan et al., 2005) ✓ ✓ ✓  
European (Dutheil et al., 2010) ✓ ✓ ✓  
*When included pesticide 
exposure 
 ✓  
 
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Figure 1.1. Model Highlighting the Composition of the BBB.  Endothelial cells form 
tight junctions with adjacent cells, preventing diffusion of polar compounds through 
paracellular pathways. Astrocytes and pericytes are present to physically reinforce the 
endothelial cell-to-cell junctions, as well as produce factors that induce the endothelial 
cells’ ability to generate tight junction proteins. Finally, an array of influx and efflux 
transporters is present and mediate transcellular transport of endogenous and xenobiotic 
compounds. Glucose transporter 1 (Glut1), Large amino acid transporter 1 (LAT1), 
Equilibrate nucleoside transporter 1 (ENT1), Multidrug resistance protein 4 (MRP4), P-
glycoprotein (P-gp), Breast cancer resistance protein (BCRP), Organic anion transporting 
polypeptide 2B1 (Oatp2B1), Organic anion transporting polypeptide 1A2 (Oatp1A2). 
Image adapted from Figure 5-10 of (Doull, 2008). 
 
	  
28	  
	  
 
 
 
Figure 1.2. Classification of Pesticides.  Pesticides are classified based on their target 
species. Of the compounds associated with Parkinson’s disease, all are classified as either 
fungicides, herbicides, or insecticides. 
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Figure 1.3. Chemical Structures of MPP+ and Paraquat. MPTP is converted to MPP+ 
(cyperquat) in the brain. One of the pyridine rings of MPP+ is charged, whereas both 
pyridine rings in paraquat are charged.  
 
	  
30	  
	  
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
ABSENCE OF P-GLYCOPROTIEN TRANSPORT IN THE  
PHARMACOKINETICS AND TOXICITY OF THE HERBICIDE PARAQUAT 
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ABSTRACT 
P-glycoprotein (P-gp) is an efflux transporter encoded by the ABCB1 (or MDR1) 
gene. ABCB1 genetic variation has been associated with Parkinson’s disease, which may 
be due to altered neurotoxicant disposition. Our goal was to investigate the role of P-gp 
transport in the disposition of the herbicide paraquat, a Parkinson’s-associated 
neurotoxicant. We utilized in vitro transporter methods of ATPase, cytotoxicity, 
transepithelial permeability, and rhodamine-123 inhibition. We also measured paraquat 
pharmacokinetics and brain distribution in FVB wild-type and P-gp-deficient (mdr1a(-/-
)/mdr1b(-/-)) mice following 10, 25, 50, and 100 mg/kg oral doses. In vitro data showed 
that: 1) paraquat failed to stimulate ATPase activity; 2) paraquat-induced cytotoxicity 
was unchanged in P-gp-expressing cells in the absence or presence of P-gp inhibitors 
verapamil and GF120918 (EC50 values of 37.0 (33.2 – 41.4), 46.2 (42.5 – 50.2), and 34.1 
(31.2 – 37.2) µM, respectively); 3) transepithelial transport of paraquat in P-gp-
expressing cells was not altered by GF120918 (efflux ratios of 1.55 ± 0.39 and 1.58 ± 
0.36, respectively); and 4) paraquat did not inhibit rhodamine-123 transport. We observed 
differences in pharmacokinetic parameters between FVB wild-type and mdr1a(-/-)/mdr1b(-
/-) mice. A clearance of 0.78 (95% CI: 0.58 – 0.98) and 0.47 L/hr (0.42 – 0.52), was 
observed in the FVB wild-type and mdr1a(-/-)/mdr1b(-/-) mice, respectively, and volume of 
distributions of 3.36 (2.39 – 4.33) and 1.77 L (1.50 – 2.04), respectively. Importantly, 
paraquat brain accumulation was the same across all doses. Together these studies 
indicate that paraquat is neither a substrate nor an inhibitor of P-gp. Therefore, the 
association between ABCB1 genetic variation and risk of Parkinson’s disease is not due 
to alterations in efflux of paraquat.  
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2.1.  INTRODUCTION 
P-glycoprotein (P-gp) is an efflux drug transporter encoded by the multidrug 
resistance gene ABCB1 (also known as MDR1). P-gp is a member of the ATP-binding 
cassette (ABC) superfamily of transporters, and mediates the efflux of a variety of 
structurally diverse xenobiotics in healthy tissues throughout the body including the 
intestine, liver, kidney, and at the blood-brain-barrier (Lin and Yamazaki, 2003a; Lin and 
Yamazaki, 2003b; Schinkel, 1997; Sharom, 2006; Sharom, 2011). P-gp plays an 
important role in the pharmacokinetics and disposition of drugs from many therapeutic 
classes [as reviewed in (Cascorbi, 2011; Giacomini, 1997; Giacomini et al., 2010; 
Sharom, 2011)]; however, there is less evidence for the role of P-gp in toxicant 
disposition. P-gp has also been associated with a number of diseases, including 
Parkinson’s disease (Bartels et al., 2008a; Drozdzik et al., 2003; Dutheil et al., 2010; 
Furuno et al., 2002; Le Couteur et al., 2001; Lee et al., 2004; Lee and Bendayan, 2004; 
Tan et al., 2005; Tan et al., 2004; Vautier and Fernandez, 2009; Westerlund et al., 2009; 
Westerlund et al., 2008). While exposure to neurotoxic xenobiotics is a well-known risk 
factor in Parkinson’s disease, it is unknown whether P-gp mediates the transport of these 
compounds (Bonnet and Houeto, 1999; Caudle et al., 2012a; Caudle et al., 2012b; Gatto 
et al., 2009; Langston et al., 1984; Semchuk et al., 1992; Steece-Collier et al., 2002).  
Paraquat dichloride, or methyl viologen, is an herbicide that has been highly 
implicated as a risk factor for Parkinson’s disease (Costello et al., 2009; Dhillon et al., 
2008; Dinis-Oliveira et al., 2006b; Liou et al., 1997; McCormack et al., 2002; Tomenson 
and Campbell, 2011). Although production and commercial sale of paraquat has been 
banned in several countries due to toxicity, paraquat remains one of the most commonly 
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used herbicides worldwide, including in the United States. In rodents, paraquat induces 
toxicity associated with the progression of Parkinson’s disease, such as increased 
dopaminergic neurodegeneration in the brain, oxidative stress, and a loss of dopaminergic 
neurons in the substantia nigra (Betarbet et al., 2000; Dinis-Oliveira et al., 2006b; Gatto 
et al., 2009; Kang et al., 2009; Koller et al., 1990; Li et al., 2005a; Li et al., 2005b; Liou 
et al., 1997; Semchuk et al., 1992; Somayajulu-Nitu et al., 2009; Tomenson and 
Campbell, 2011; Yang et al., 2007).  
Some studies have suggested a link between P-gp activity and paraquat exposure. 
Specifically, two studies found that induction of P-gp in rat lungs was protective against 
paraquat-induced lung toxicity (Dinis-Oliveira et al., 2006a; Dinis-Oliveira et al., 2006c). 
If paraquat was a P-gp substrate, decreased P-gp activity at the blood-brain-barrier could 
lead to increased brain accumulation of paraquat and an increased risk of Parkinson’s 
disease. One mechanism for decreased P-gp function is due to genetic variation in the 
ABCB1 gene, which is highly polymorphic with more than 300 single nucleotide 
polymorphisms (SNPs) in the coding region alone. Of these SNPs, four in particular 
(1199G>A, 1236C>T, 2677G>T/A, and 3435C>T) have been shown to alter P-gp 
expression or activity [as reviewed in (Cascorbi, 2011; Chinn and Kroetz, 2007; Wang 
and Sadee, 2006; Woodahl and Ho, 2004)].  
The goal of this study was to evaluate P-gp-mediated transport of paraquat in a 
combination of in vitro and in vivo models to evaluate a potential mechanism for the role 
of P-gp in Parkinson’s disease. We characterized P-gp transport of paraquat in vitro using 
cell- and membrane-based models. We also used an animal model to determine paraquat 
pharmacokinetics and brain accumulation in FVB wild-type and P-gp deficient mice 
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(mdr1a(-/-)/1b(-/-)) to evaluate the role of P-gp in paraquat disposition in vivo. This is the 
first comprehensive study to evaluate P-gp-mediated disposition of paraquat. 
 
 
2.2.  MATERIALS AND METHODS 
2.2.1.  Chemicals 
Paraquat dichloride, doxorubicin, verapamil, rhodamine-123 (R123), 
cyclosporine, and 4',6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-
Aldrich Chemical Company (St. Louis, MO). GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-
6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine 
carboxamide] was kindly provided by GlaxoSmithKline (Research Triangle Park, NC). 
14C-paraquat was purchased from American Radiolabeled Chemicals (St. Louis, MO).  
 
2.2.2.  ATPase Activity  
Stimulation of ATPase activity was measured using SB MDR1/P-gp Sf9 ATPase 
membranes (SOLVO Biotechnology, Budaors, Hungary) according to the manufacturer’s 
instructions. ATPase activity in the presence of xenobiotics was estimated by measuring 
the release of inorganic phosphate (Pi) in a colorimetric reaction. P-gp membranes were 
incubated with either paraquat or the known P-gp substrate verapamil over a 
concentration range of 0.05 - 100 µM. ATPase activity was determined as the difference 
in Pi liberation measured in the absence or presence of 1.2 mM sodium orthovanadate, a 
non-specific ATPase inhibitor. The reactions were incubated at 37°C for 20 min and 
stopped by the addition of 10% SDS. The detection reagent containing ammonium 
molybdate was added and incubated for 25 min at 37°C, and absorbance was read at 690 
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nm using a SpectraMax Gemini XS microplate reader (Molecular Devices, Sunnyvale, 
CA). The amount of Pi liberation was calculated from a phosphate standard curve. 
ATPase activity was reported as nmol Pi liberated per min incubation time per mg total 
protein (nmol Pi/min/mg protein). Compounds were evaluated in duplicate, and the assay 
was repeated twice. Michaelis-Menten parameters (Vmax and Km) were estimated using a 
nonlinear regression least squares model fit on Prism 5.0 software (GraphPad, San Diego, 
CA). 
 
2.2.3.  Cell Culture 
The porcine renal epithelial cell line LLC-PK1 was utilized in the in vitro models 
of transport. LLC-PK1 vector cells (LLC-vector) and recombinant ABCB1/MDR1 cells 
(LLC-MDR1-WT), generously provided by Michael M. Gottesman in the Laboratory of 
Cell Biology at the National Cancer Institute (Bethesda, MD), were cultured in complete 
Media 199 (Mediatech, Manassas, VA) supplemented with 3% (v/v) fetal bovine serum 
(FBS) (Mediatech), 1% (v/v) L-glutamine (Mediatech), 1% (v/v) penicillin/streptomycin 
(Mediatech), and 1% (v/v) geneticin (Life Technologies, Carlsbad, CA) and grown at 
37°C in the presence of 5% CO2.  
 
2.2.4.  Cytotoxic Sensitivity  
Sensitivity to cytotoxic agents was evaluated in LLC-vector and LLC-MDR1-WT 
cells plated overnight at a density of 1000 cells/well in 96-well plates (Fischer Scientific, 
Hampton, New Hampshire). Cells were treated with either paraquat (concentration range 
of 15 - 250 µM), doxorubicin (concentration range of 0.05 nM - 250 µM), or colchicine 
(concentration range of 0.01-50,000 µM) for 72 hrs at 37°C. Cell viability was evaluated 
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using the CellTiter-Glo® Cell Viability Assay (Promega, Fitchburg, WI) according to the 
manufacturer’s instructions. Inhibition was performed at 0.5 µM GF120918 and 10 µM 
verapamil. Luminescence was measured using a SynergyMX microplate reader (Biotek, 
Winooski, VT). Compounds were evaluated in triplicate. Viability was estimated as the 
effective concentration necessary for 50% cell death (EC50) based on a nonlinear 
regression log (agonist) vs. response variable slope least squares model fit using Prism 
5.0.  
 
2.2.5.  Transepithelial Permeability   
Transepithelial permeability assays were completed according to methods 
developed previously (Woodahl et al., 2009a; Woodahl et al., 2004; Woodahl et al., 
2005). Briefly, LLC-vector and LLC-MDR1-WT recombinant cells were plated at a 
density of 2 x 106 cells/24 mm well on permeable supports (Transwell; 3.0 µm membrane 
pore size; Corning, (Tewksbury, MA)) and grown for 4 days prior to the initiation of the 
experiment. Transepithelial electrical resistance (TEER) values were measured with a 
Millicell-ERS (Millipore, Billerica, MA). All transport assays were carried out at 37°C 
and corrections were made for the difference in volume in the apical and basolateral 
compartments. Transport of the known P-gp substrate, R123 (5 µM), or 14C-paraquat 
(450 nM) was performed in serum-free Media 199. Inhibition of transport was performed 
at 1 µM GF120918. Aliquots of 50 µl were taken from the apical and basal compartments 
at 0.5, 1, 2, 3, and 4 hrs. Experiments were run in triplicate. R123 was quantified by 
measuring fluorescence with an excitation of 488 nm and an emission of 525 nm using a 
Gemini XS Fluorescent microplate reader (Molecular Devices, Sunnyville CA). 14C-
 
	  
37	  
	  
paraquat was quantified by liquid scintillation counting (Beckman LS 6500, Brea, CA). 
Apparent permeability (Papp) was calculated as Papp = (1/(A × C0)) × (dQ/dt) where A is 
the surface area of the permeable support, C0 is the initial concentration in the donor 
compartment, and dQ/dt is the rate of transfer of compound into the acceptor 
compartment; Papp was estimated in both the apical-to-basolateral (Papp A→B) and 
basolateral-to-apical (Papp B→A) directions. The permeability efflux ratio of (Papp B→A)/ (Papp 
A→B) was estimated to evaluate P-gp-mediated directional efflux. Permeability ratios >2 
are expected for P-gp substrates, and the ratio should reduce to approximately 1.0 in the 
presence of the P-gp inhibitor GF120918.  
 
2.2.6.  Intracellular Accumulation  
 Inhibition of R123 intracellular uptake in LLC-vector and LLC-MDR1-WT cells 
was performed based on a previously developed assay (Woodahl et al., 2004), with the 
following modifications. Cells were plated overnight at a density of 1 x 106 cells/well in 
6-well plates (Invitrogen). Cells were incubated in triplicate in 5 µM R123 with and 
without inhibitors in serum-free Media 199 at 37°C and then allowed to efflux in the 
presence of inhibitor in complete Media 199. Concentrations ranged from 0.1 - 1000 µM 
for paraquat, 0.1 - 500 µM for verapamil, 0.1 - 100 µM for cyclosporine, and 1.56 nM - 1 
µM for GF120918. After the efflux period, cells were washed in ice-cold phosphate 
buffered saline (PBS), trypsinized, and resuspended in PBS containing 5 mM EDTA, 25 
mM HEPES, and 1% FBS (pH 7.0). Immediately prior to flow cytometry, DAPI was 
added to the cells as a measure of cell viability. Cells were analyzed with a FACSAriaII 
flow cytometer (BD Biosciences, San Jose, CA) using FACSDiva software. Ten thousand 
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cells from each sample were analyzed for forward scatter, side scatter, DAPI, and R123 
accumulation. Inhibition was estimated as the inhibitor concentration necessary for 50% 
inhibition (IC50) based on a nonlinear regression log (inhibitor) vs. normalized response 
variable slope least squares model fit on Prism 5.0. 
  
2.2.7.  Animals 
Male FVB wild-type and mdr1a(-/-)/1b(-/-) (FVB background) mice age 1-8 months 
(Taconic Farms, Germantown, NY) were used in this study. Mice were maintained on a 
12 hr light-dark cycle, housed in microisolators, and were given food and deionized water 
ad libitum. All procedures were approved by the University of Montana Institutional 
Animal Care and Use Committee. 
 
2.2.8.  Paraquat Dosing and Sample Collection 
Paraquat was prepared fresh in sterile water for each treatment. Paraquat was 
administered via oral gavage at doses of 10, 25, 50, or 100 mg/kg (n = 5-10 per dose 
group). Blood samples were collected via the saphenous vein at 1, 2, 4, and 8 hrs 
following paraquat administration, and plasma was separated from whole blood via 
centrifugation. Paraquat administration occurred at approximately the same time of day 
for each treatment. Following the 8 hr blood collection, mice were euthanized via 
cervical dislocation. Whole brains were extracted and washed twice in PBS. Plasma and 
brain samples were frozen at -80°C until analysis.  
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2.2.9.  Quantitation of Paraquat in Plasma and Brain Samples 
After thawing, sterile water was added to the brain samples at a 2:1 (w:v) ratio. 
The brain:water mixture was first homogenized for 1 min and then sonicated for 5 sec 
intervals for a total of 1 min; samples were kept on ice throughout the entire 
homogenization and sonication period. Ethyl viologen (100 µg/L) was used as an internal 
standard in plasma and brain samples prior to protein extraction. Standard curves were 
simultaneously prepared from brain and plasma samples from untreated mice at a range 
of 10- 2500 µg/L paraquat and 100 µg/L ethyl viologen. Plasma and brain samples were 
extracted with 1:2 (v:v) acetonitrile (-20°C), vortexed, and centrifuged at 13,000 rpm for 
10 min. The supernatant was collected and the extraction was repeated two more times 
for a total of three extractions. Supernatants were combined and filtered using Ultrafree-
MC centrifugal filter units (Millipore). Samples were stored at -80°C prior to 
quantitation. 
Levels of paraquat in mouse plasma and brain samples were determined by liquid 
chromatography tandem mass spectroscopy (LC-MS/MS) using an Agilent 1200 Series 
HPLC and 6300 series MSD/XCT (Waldbronn, Germany), utilizing a method adapted 
from previously published work (Ariffin and Anderson, 2006). Separations were 
accomplished using a Phenomenex Kinetex® C18 column (Torrance, CA), 2.1x100 mm, 
2.6 µm particles, and a flow rate of 0.1 mL/min. A gradient from 25% to 90% of 
methanol (mobile phase B) over 4 min was employed with 20 mM ammonium formate 
and 15 mM heptafluorobutyric acid in water (mobile phase A; pH 3.2). MS detection was 
made from 5-10 min for plasma samples and 3.5-10 min for brain samples with all other 
flow diverted to waste. Quantitation of paraquat in plasma or brain samples was 
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determined using multiple reaction monitoring to characterize fragmentation of singly-
charged analytes with transitions m/z 185→171 for paraquat and m/z 213→157 for ethyl 
viologen. Basic MS settings included nebulizer pressure 40 psi, dry gas flow 8 L/min, dry 
gas temperature 350°C, isolation window 4.0 amu, and fragmentation amplitude 0.41 V. 
Plasma and brain concentrations were reported as µg/L and ng/g brain tissue, 
respectively.  
 
2.2.10.  Pharmacokinetic Analysis 
Initial pharmacokinetic parameter estimates were made using standard non-
compartmental methods (Phoenix™ WinNonlin® 6.3, Pharsight, St. Louis, MI) 
(Gabrielsson and Weiner, 2012). When possible the linear trapezoidal method with the 
“partial area” option of 0 to 8 hrs was used in each strain of mouse to estimate the 
elimination rate constant based on available observations and the area under the plasma 
concentration-time curve (AUC). In instances where calculation of the elimination rate 
constant was not possible, the AUC was calculated up to the last observation. Initial 
estimates of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) 
were calculated using standard equations. The concentration-time profile of paraquat was 
explored graphically. 
Final pharmacokinetic parameters were estimated using a population 
pharmacokinetic analysis of paraquat and nonlinear mixed effect modeling (NONMEM, 
version 7.2, ICON Dev. Soln., Ellicott City, MD) with PDx-Pop® (version 5, ICON Dev. 
Soln., Ellicott City, MD) interfaced with Xpose® (version 4.0, release 6, update 1, 
Uppsala, Sweden) (Yuh et al., 1994). Using the subroutines of NONMEM: ADVAN 2 
(one compartment linear model with first order absorption) and TRANS 2 (CL/F and 
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V/F), population pharmacokinetic estimates of CL/F, V/F, and absorption rate constant 
(ka) were estimated by combining all dose groups in each mouse strain. Robust estimates 
for interindividual variability (IIV), which is the source of variability determined between 
mice, were predicted. Residual unexplained variability (RUV), the coefficient of variance 
that accounts for the random and unexplained variability, was also determined. Paraquat 
brain-to-plasma partitioning ratios were calculated using the paraquat concentrations in 
brain (ng/g) and plasma (µg/L) at the 8 hr time point.  
 
2.2.11.  Model Evaluation 
The population pharmacokinetic models were compared using the Akaike and 
Schwarz information criterion to discriminate between non-hierarchical models in the 
selection of the structural model. During model development, diagnostic plots of 
observed vs. population predicted or individual predicted values were used to visually 
assess model fit (Sherwin et al., 2012). Plots of residuals and weighted residuals vs. time 
or predicted values were also examined. The population pharmacokinetic models were 
evaluated using a non-parametric re-sampling bootstrap method to assess model accuracy 
and stability. PDx-Pop® (Dublin, Ireland) was used to generate bootstrap runs generated 
by random sampling using the original dataset. Standard errors for the estimated 
population parameters and random effects error models were also assessed. Relative 
standard error (RSE) was estimated as the standard error divided by the mean and 
expressed as a percentage. Random error is considered to always be present and is 
unpredictable (Sheiner and Beal, 1981). Empirical Bayesian estimates for the predicted 
concentrations were obtained using the POSTHOC option in NONMEM. The 
performance of the final model was further evaluated by generating a visual predictive 
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check, which compares statistics derived from the distribution of observations and the 
distribution of predictions (Bergstrand et al., 2011).  
 
2.2.12.  Statistical Analysis  
Student’s one- or two-tailed t test was used to determine differences between two 
sets of data for transepithelial permeability. An extra sum of squares F-test was utilized to 
compare individual parameters for the cytotoxic sensitiviy assay. The null hypothesis was 
that the EC50 estimates are the same within a cell type between xenobiotic treatment 
group alone and in the presence of a P-gp inhibitor, and the null hypothesis was only 
rejected if the inhibitor decreased cytotoxic resistance. A two-tailed Grubbs’ test for 
outliers was utilized prior to analysis of paraquat pharmacokinetics in plasma and brain 
samples. Levels of paraquat in brain samples were analyzed using an analysis of 
variances (ANOVA). For all analyses, p-values of < 0.05 were considered statistically 
significant.  
 
2.3.  RESULTS 
ATPase activity stimulated by paraquat was measured in P-gp membranes using 
the P-gp substrate verapamil as a positive control (Figure 2.1., page 54). Vmax and Km 
parameters for verapamil were estimated as 48.4 ± 2.6 nmol Pi/min/mg protein and 2.54 ± 
0.68 µM, respectively. Paraquat did not stimulate ATPase activity above the level of the 
sodium orthovanadate-sensitive control (11.4 ± 4.3 nmol Pi/min/mg protein), indicating 
that paraquat is not a P-gp substrate.  
Xenobiotic-induced cytotoxicity was measured in LLC-vector and LLC-MDR1-
WT cells. Dose-response curves were generated following exposure to paraquat two 
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cytotoxic P-gp substrates, doxorubicin and colchicine, and EC50 values were estimated 
(Figure 2.2. and Table 2.1., pages 55 and 51 respectively). We also utilized P-gp 
inhibitors GF120918 and verapamil to confirm changes in cellular sensitivities were due 
to P-gp. As expected, LLC-MDR1-WT cells exhibit significantly increased resistance to 
doxorubicin (61-fold) and colchicine (48-fold) when compared with the LLC-vector cells 
(Figures 2.2., a-b and c-d, respectively, page 55). In addition, P-gp inhibitors, GF120918 
and verapamil, reversed cellular resistance to doxorubicin  and colchicine in LLC-
MDR1-WT cells. Conversely, we observed a slight increase in resistance to paraquat 
toxicity in LLC-MDR1-WT cells compared to LLC-vector (3-fold) (Table 2.1., page 51). 
Importantly, the P-gp inhibitors GF120918 and verapamil, however, had no effect on 
paraquat-induced cytotoxicity (Figure 2.2. e-f, page 55) indicating that the modest 
increase in resistance to paraquat in LLC-MDR1-WT cells was not P-gp-mediated. This 
provided further evidence that paraquat is not a P-gp substrate.  
P-gp-mediated directional transport in LLC-vector or LLC-MDR1-WT cells was 
evaluated by estimating transepithelial permeability efflux ratios using the P-gp substrate 
R123 as a positive control (Table 2.2., page 52). TEER values were measured as 676 ± 
157 and 782 ± 174 Ω*cm2 in LLC-vector and LLC-MDR1-WT cells, respectively, prior 
to the start of experiments confirming integrity of the monolayers. Experiments were 
performed up to 4 hours to ensure that permeability rates were estimated in the linear 
range.  As expected, we observed directional P-gp-mediated transport of R123 in LLC-
MDR1-WT when compared LLC-vector cells, and the efflux was inhibited by 
GF120918. There was no directional transport of 14C-paraquat in LLC-vector or LLC-
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MDR1-WT cells and no effect of GF120918, confirming that paraquat is not a P-gp 
substrate. 
Paraquat was also evaluated as an inhibitor of P-gp. The ability of paraquat to 
inhibit the intracellular accumulation of R123 in LLC-vector and LLC-MDR1-WT cells 
was measured and compared to known P-gp inhibitors verapamil, cyclosporine, and 
GF120918 (Figure 2.3., page 56). Verapamil, cyclosporine, and GF120928 inhibited 
R123 efflux with IC50 values of 1.98 ± 0.12 µM, 1.39 ± 0.07 µM, and 22.9 ± 1.9 nM, 
respectively. Paraquat did not inhibit R123 accumulation in P-gp-expressing cells across 
a broad concentration range.  
The systematic screening or paraquat in vitro indicates that paraquat is not a 
substrate of P-gp, but to confirm this finding  we next investigated the role of P-gp in the 
disposition of paraquat in vivo. Paraquat pharmacokinetics and brain accumulation in 
FVB wild-type and mdr1a(-/-)/1b(-/-) mice were evaluated. The absence of mdr1a and 
mdr1b in the knock-out mice was confirmed by genotyping both FVB wild-type and 
mdr1a(-/-)/1b(-/-) mice using methods obtained from Taconic Farms (Figure 2.4., page 57). 
Both  wild-type and knock-out strains of mice have similar plasma concentration-time 
curves following oral administration of 10, 25, 50, or 100 mg/kg paraquat (Figures 2.5a 
and 2.5b, page 58). After validating the model by non-compartmental analysis and 
generating initial parameter estimates (data not shown), we used the estimates in the 
generation of a one-compartment pharmacokinetic model to estimate final 
pharmacokinetic parameters (Table 2.3., page 53). Visual inspection of the plasma 
concentration time curves suggested that the majority of absorption had occurred prior to 
obtaining the first sample making it difficult to estimate the absorption rate constant, 
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particularly in the mdr1a(-/-)/1b(-/-) mice. Therefore, the estimate for absorption in the 
population pharmacokinetic model used the predicted estimate obtained from the non-
compartmental analysis and is expressed as a fixed estimate in the mdr1a(-/-)/1b(-/-) mice. 
There were modest differences in CL/F and V/F between FVB wild-type and mdr1a(-/-
)/1b(-/-) mice; however, the effect was small with less than a 2-fold increase in each 
parameter in the mdr1a(-/-)/1b(-/-) mice. Importantly, there were no differences between 
FVB wild-type and mdr1a(-/-)/1b(-/-) mice in brain-to-plasma partitioning ratios of paraquat 
calculated from combined dose groups (2.39 ± 1.57 and 1.92 ± 1.62, respectively) or total 
brain paraquat accumulation across dose groups (Figure 2.6., page 59). The lack of a 
difference in brain distribution between FVB wild-type and mdr1a(-/-)/1b(-/-) mice 
confirms that paraquat is not a P-gp substrate 
 
2.4 DISCUSSION 
We have systematically evaluated the P-gp-mediated transport of paraquat using a 
combination of in vitro and in vivo models. We determined that paraquat is neither a 
substrate nor an inhibitor of P-gp. Although there is evidence to show that P-gp is 
associated with the development of Parkinson’s disease, these data demonstrate that the 
causal relationship is not due to the P-gp-mediated disposition of the herbicide paraquat.  
Several methods confirmed that P-gp does not transport paraquat. Paraquat was 
screened as a substrate for P-gp in three experimental models: ATPase activity, 
xenobiotic-induced cytotoxicity, and transepithelial permeability, all of which have been 
well characterized to study P-gp (Brouwer et al., 2013; Feng et al., 2008; Giacomini et 
al., 2010; Polli et al., 2001). First, paraquat did not stimulate the hydrolysis of ATP in P-
gp expressing membranes. Although the ATPase assay is a great screening tool to 
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investigate potential substrates of P-gp, it has been reported to generate false negatives 
(Bircsak et al., 2012), and this assay may not be appropriate for slowly transported 
substrates.  Thus, we moved forward in assessing paraquat as a P-gp substrate in a cell 
based model. LLC-PK1 have low endogenous expression levels of transporters as well as 
differentiate in to polarized monolayers, and express tight junction proteins, similar to the 
cells of the BBB (Giacomini et al., 2010), making the LLC-PK1 cell line the gold 
standard cell line for transport evaluations.  We utilized recombinant LLC-MDR1-WT 
and LLC-Vector cells as well as a combination of cytotoxic P-gp substrates and known P-
gp inhibitors to assure our cell models contained multiple controls and were as robust as 
possible. We found that P-gp expression did not alter sensitivity to paraquat-induced 
cytotoxicity in cells, and there was no directional transepithelial transport of paraquat 
mediated by P-gp. Paraquat also did not inhibit R123 efflux in P-gp-expressing cells. 
Therefore, we can conclude from the in vitro studies that paraquat is not a human P-gp 
substrate or inhibitor.  
  To confirm our in vitro studies, we next evaluated paraquat pharmacokinetics and 
brain accumulation following an oral dose escalation study between FVB wild-type and 
mdr1a(-/-)/1b(-/-) mice. We observed subtle differences in the primary pharmacokinetic 
parameters between wild-type and knock-out mice. For example there was a significant 
increase in CL/F in mdr1a(-/-)/1b(-/-) mice when compared to FVB wild-type. However, it 
is clear that this change is not due to P-gp transport because if paraquat was a P-gp 
substrate then the mdr1a(-/-)/1b(-/-) mice would display decreased CL/F of paraquat as these 
mice are lacking P-gp not only at the BBB, but also at the intestine, kidney, and liver.  
Our studies indicate the opposite effect, lack of P-gp results in increased CL/F; clearly 
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there must be other systemic changes in the mdr1a(-/-)/1b(-/-)  mice as a result of no 
systemic P-gp expression.  It is most notable that we did not observe differences in brain-
to-plasma partitioning or total brain accumulation of paraquat between FVB wild-type 
and mdr1a(-/-)/1b(-/-) mice. Although one would expect a decrease in CL/F if paraquat was 
a P-gp substrate, the most notable expectation would be the significant increase in brain 
distribution of paraquat. Drugs that are P-gp substrates, such as amprenavir, ivermectin or 
vinblastine, display approximately 20-80-fold increase in brain accumulation in knock-
out mice relative to wild-type mice due to loss of P-gp activity at the blood-brain-barrier 
(Polli et al., 1999; Schinkel et al., 1994; van Asperen et al., 1996). It is known that 
alterations in drug-metabolizing enzymes and drug transporters occur in mdr1a(-/-)/1b(-/-) 
mice that may account for the observed differences in paraquat pharmacokinetics 
(Schuetz et al., 2000); it is clear, however, from the lack of differential brain distribution 
of paraquat that these differences are not due to P-gp and that P-gp is not playing a role in 
paraquat disposition. The animal studies confirm our in vitro results that paraquat is not a 
human or mouse P-gp substrate.  
Our study is the first comprehensive study to measure P-gp transport of paraquat 
both in vitro and in vivo. Previous studies in rats have found that induction of P-gp 
expression was protective against paraquat-induced toxicity, which would suggest that 
paraquat is a P-gp substrate (Dinis-Oliveira et al., 2006a; Dinis-Oliveira et al., 2006c). 
These studies, however, used non-selective P-gp inducers, dexamethasone and 
doxorubicin, which are know to be broad-spectrum inducers of not only other drug 
transporters but drug-metabolizing enzymes as well; therefore, several mechanisms other 
than P-gp may have been involved in the protection against paraquat toxicity. This same 
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group also examined P-gp transport of paraquat in Caco-2 cells following induction of P-
gp by doxorubicin using paraquat concentrations ranging from 10-5000 µM. The 
researchers found less than a 2-fold increase in the reported EC50 values as a result of 
doxorubicin treatment, indicating a minimal protective effect by P-gp (Silva et al., 2011). 
We also observed a 3-fold increase in paraquat resistance between P-gp-expressing and 
non-expressing cells, but importantly observed no effect of P-gp inhibitors on the 
resistance, indicating that P-gp was not contributing to the observed effect. As a 
comparison, known P-gp substrates, doxorubicin and colchicine, exhibited marked 
increases in resistance, 61-fold and 48-fold, respectively, between P-gp-expressing and 
non-expressing cells and resistance was reversed in the presence of P-gp inhibitors. 
Finally, another study evaluating paraquat as a P-gp substrate in Caco-2 cells observed 
differential paraquat cytotoxicity between untreated and doxorubicin-induced cells, but 
only at paraquat concentrations of 1 mM and above (Silva et al., 2013). These 
concentrations far exceed reported paraquat concentrations in humans. Blood samples 
from patients with acute paraquat poisoning had measured plasma concentrations of 
paraquat that did not exceed 50,000 ng/ml paraquat, or 194 µM, and most patients’ 
concentrations were significantly lower (Shi et al., 2012). Thus, evaluating P-gp transport 
of paraquat in the mM concentration range is inappropriate and not relevant to systemic 
paraquat exposures in humans. 
While this is the first study to evaluate the role of P-gp in paraquat 
pharmacokinetics, there have been other studies to measure paraquat pharmacokinetics in 
chronic studies (Breckenridge et al., 2013; Prasad et al., 2009; Prasad et al., 2007). The 
paraquat plasma concentrations we observed, following an oral dose to FVB mice, were 
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approximately a magnitude less than what has been observed following an intraperitoneal 
dose to C57BlJ/6 mice; correspondingly, the paraquat brain concentrations we observed 
were also lower (Breckenridge et al., 2013; Prasad et al., 2009; Prasad et al., 2007). These 
differences in paraquat pharmacokinetics may be due to the different mouse strains 
studied and different dosing strategies given that paraquat has variable bioavailability 
depending on the route of administration (Chui et al., 1988).  
Several studies have described an association between ABCB1 pharmacogenomics 
and susceptibility to Parkinson’s disease (Bartels et al., 2008a; Drozdzik et al., 2003; 
Dutheil et al., 2010; Furuno et al., 2002; Le Couteur et al., 2001; Lee et al., 2004; Lee and 
Bendayan, 2004; Tan et al., 2005; Tan et al., 2004; Vautier and Fernandez, 2009; 
Westerlund et al., 2009; Westerlund et al., 2008). One mechanism may be that ABCB1 
genetic variation decreases P-gp activity at the blood-brain-barrier, leading to increased 
brain accumulation of neurotoxicants, and an increased incidence of Parkinson’s disease. 
In European populations, the 1236C>T and 3435C>T SNPs have been shown to have an 
increased frequency in Parkinson’s disease, while another study evaluating the 
2677G>T/A and 3435C>T SNPs found no association between allele frequencies and 
Parkinson’s disease (Furuno et al., 2002; Tan et al., 2004). Studies in Asian patients 
showed that the 2677T/3435T or 1236T/2677T/3435T haplotypes were significantly 
associated with a reduced risk of Parkinson’s disease (Lee et al., 2004; Tan et al., 2005). 
Finally, a recent study in Europeans observed an association between ABCB1 variation 
and Parkinson’s disease risk, but only after including occupational exposure to 
organochlorine pesticides in the analysis; the researchers observed a higher risk of 
Parkinson’s disease in patients with 2677TT or TA genotypes who were also exposed to 
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organochlorines (Dutheil et al., 2010). Some of these conflicting associations with 
ABCB1 pharmacogenomics and Parkinson’s disease could be a result of small sample 
sizes as well as genetic heterogeneity within the study populations. In addition to 
pharmacogenetic evidence, another link to P-gp activity in Parkinson’s disease were 
studies that showed increased brain accumulation of verapamil in Parkinson’s disease 
patients compared to control subjects, indicating that P-gp activity at the blood-brain-
barrier may be decreased (Bartels et al., 2008a; Kortekaas et al., 2005). While there is 
evidence for a role of P-gp in the development of Parkinson’s disease, it is clear from our 
data that altered P-gp transport of paraquat is not the cause. 
 
2.4 CONCLUSIONS 
In summary, we have demonstrated in both in vitro and in vivo models that 
paraquat is not a substrate or inhibitor of P-gp. Namely, P-gp expression did not alter the 
brain distribution of paraquat in mdr1a(-/-)/1b(-/-)  mice. Therefore, the association of 
ABCB1 genetic variation and the increased risk of developing Parkinson’s disease is not 
due to alterations in P-gp efflux of the herbicide paraquat. Further research is needed to 
identify neurotoxicants that may play a role in the ABCB1 pharmacogenetic associations 
with Parkinson’s disease. 
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Table 2.1. Xenobiotic-induced Cytotoxicity in LLC-vector and LLC-MDR1-WT 
Cells  
 EC50 Values (95% Confidence Interval) 
 LLC-vector LLC-MDR1-WT 
Paraquat (µM) 12.8 (11.4 – 14.3) 37.0 (33.2 – 41.4) 
Paraquat (µM) + GF120918 13.6 (12.4 – 15.0) 46.2 (42.5 – 50.2) 
Paraquat (µM) + Verapamil 12.9 (10.9 – 15.4) 34.1 (31.2 – 37.2) 
Doxorubicin (nM) 32.2 (13.7 – 85.6) 1978 (1015-3850) 
Doxorubicin (nM) + GF120918 24.8 (12.0 – 51.3) 8.06 (1.32 – 49.2)a 
Doxorubicin (nM) + Verapamil 43.4 (12.0 – 155.9) 268 (90.7 – 98.6)a 
Colchicine (µM) 13.3 (out of range) 645 (467 – 892) 
Colchicine (µM) + GF120918 12.6 (10.8 – 14.5) 17.5 (12.0 – 25.4)a 
Colchicine (µM) + Verapamil 12.8 (out of range) 179 (117 – 273)a 
Significant differences within a cell type between xenobiotic treatment group alone and 
in the presence of a P-gp inhibitor; p < 0.0005a. 
* n.d.: not determined. Nonlinear regression was unable to estimate confidence intervals. 
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Table 2.2. Transepithelial Permeability in LLC-vector and LLC-MDR1-WT Cells 
 
 Papp B→A/Papp A→B ± s.d. 
 LLC-vector LLC-MDR1-WT 
R123 1.12 ± 0.40 5.10 ± 2.19 
R123 + GF120918 1.13 ± 0.29 1.33 ± 0.92 
Paraquat 1.39 ± 0.43 1.55 ± 0.39 
Paraquat + GF120918 1.29 ± 0.35 1.58 ± 0.36 
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Table 2.3. Population Pharmacokinetic Analysis of Paraquat in FVB Wild-type and mdr1a(-/-)/1b(-/-) Mice Following a Single 
  
Paraquat Oral Dose  
 
 FVB wild-type (n=34)  mdr1a(-/-)/1b(-/-) (n=28) 
 Estimates % RSE 95% CI CV%  Estimates % RSE 95% CI CV% 
CL/F (L/hr) 0.473 5.18 0.425 – 0.521 –  0.777a 13.3 0.575 – 0.979 – 
V/F (L) 1.77 7.91 1.50 – 2.04 –  3.36a 14.8 2.39 – 4.33 – 
ka 1.81 16.9 1.21 – 2.41 –  5.60b – – – 
IIV – CL/F 0.056 35.1 0.018 – 0.095 23.7  0.344 32.0 0.128 – 0.560 58.7 
IIV – V/F 0.072 49.6 0.002 – 0.141 26.8  0.514 24.7 0.265 – 0.763 71.7 
RUV (%) 0.118 23.3 0.064 – 0.172 34.4  0.133 22.5 0.074 – 0.192 36.5 
CL/F: apparent oral clearance; V: apparent volume of distribution; ka: absorption rate constant; IIV: interindividual variability; RUV: 
residual unexplained variability; RSE: relative standard error; 95% CI: ninety-five percent confidence interval; CV%: percent 
coefficient of variance; – not determined in the model 
a Significant differences between mouse strains; p < 0.005. 
b  Fixed pharmacokinetic estimate from non-compartmental analysis. 
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Figure 2.1. ATPase Activity in SB MDR1/P-gp Sf9 Membranes. P-gp membranes 
were incubated with either paraquat (closed triangle) or the known P-gp substrate 
verapamil (closed circle) over a concentration range of 0.05 - 100 µM. ATPase activity 
was determined as the difference in Pi liberation measured in the absence or presence of 
1.2 mM sodium orthovanadate (verapamil + sodium orthovanadate, open square).  
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2.2.a LLC-vector     2.2.b LLC-MDR1-WT 
	    
2.2.c LLC-vector     2.2.d LLC-MDR1-WT 
	   	  
2.2.e LLC-vector     2.2.f LLC-MDR1-WT 
	    
 
Figure 2.2. Paraquat Cytotoxic Sensitivity in LLC-vector and LLC-MDR1-WT 
Cells. Cells were treated with either doxorubicin (a-b, concentration range of 0.05 nM - 
250 µM), or colchicine (c-d, concentration range of 0.01-50,000 µM) paraquat (e-f, 
concentration range of 15 - 250 µM), (square, solid line). Cell viability was evaluated 
using the CellTiter-Glo® Cell Viability Assay. Inhibition was performed at 0.5 µM 
GF120918 (triangle, dashed line) and 10 µM verapamil (circle, dotted line).  
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Figure 2.3. Inhibition of Rhodamine-123 Transport. Data is presented a percent of 
rhodamine-123 inhibition and values are mean ± SEM. Tested compounds are paraquat 
(open triangle ), GF120918 (closed star), verapamil (open diamond), and cyclosporine 
(closed triangle).  
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Figure 2.4. Genotype of FVB Wild-type and mdr1a(-/-)1b(-/-) Mice.  Lanes 1, 6, 7, and 
13: DNA base pair (bp) standard; lanes 2 and 3: 50ng FVB wild-type mdr1a; lanes 4 and 
5: 50ng mdr1a(-/-); lanes 8 and 9: 50ng FVB wild-type mdr1b; lanes 10 and 11: 50ng 
mdr1b(-/-). FVB wild-type mdr1a and mdr1b bands at 269 and 540 bp, respectively; 
mdr1a(-/-)  and mdr1b(-/-) bands at 461 and 453 bp respectively.  
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Figure 2.5. Paraquat Plasma Concentration-time Curves in FVB Wild-type and mdr1a(-/-)/1b(-/-) Mice. Paraquat was orally 
administered at doses of 10 (circles), 25 (squares), 50 (diamond), or 100 mg/kg (triangle) to 2.5a) FVB wild-type and 2.5b) mdr1a(-/-
)/1b(-/-) mice. Plasma samples were collected at 1, 2, 4, and 8 hrs. Data are presented as mean paraquat plasma concentrations with 
error bars for standard deviation.
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Figure 2.6. Paraquat Brain Accumulation in FVB Wild-type and mdr1a(-/-)/1b(-/-) 
Mice. Brains were collected at 8 hrs after oral administration of paraquat at doses of 10, 
25, 50, or 100 mg/kg to FVB wild-type (closed squares) or mdr1a(-/-)/1b(-/-) mice (open 
squares). Data are presented as mean paraquat brain accumulation with error bars for 
standard deviation. 
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CHAPTER 3 
 
 
 
P-GLYCOPROTEIN TRANSPORT OF  
PARKINSON’S DISEASE-ASSOCIATED PESTICIDES 
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ABSTRACT 
 Pesticides exposure is associated with Parkinson’s disease and pharmacogenomic 
studies have associated the gene that encodes P-glycoprotein (P-gp), ABCB1, with 
Parkinson’s disease risk, however evidence is missing whether pesticides are P-gp 
substrates. We used three in vitro transport models to screen diazinon, dieldrin, 
endosulfan, maneb, MPP+ and rotenone as P-gp substrates and inhibitors. We also 
screened the pesticide ivermectin, which although not related to Parkinson’s disease risk, 
has been reported to be a P-gp substrate. Only rotenone stimulated ATPase activity in P-
gp-expressing membranes with Vmax and Km of 32.4 ± 1.64 nmol Pi/min/mg protein and 
1.78 ± 0.55 µM, respectively, compared to the known P-gp substrate verapamil with Vmax 
and Km of 48.4 ± 2.58 nmol Pi/min/mg protein and 2.54 ± 0.68 µM, respectively. None of 
the other pesticides stimulated ATPase activity. We observed no differential cytotoxicity 
to any of the pesticides in LLC-vector and LLC-MDR1-WT cells in the absence or 
presence of P-gp inhibitors GF120918 or verapamil. Only ivermectin inhibited the P-gp 
transport of rhodamine-123 with an IC50 of 0.252 ± 0.048 µM; the other pesticides did 
not inhibit P-gp at concentrations up to 1000 µM. We have screened the primary 
pesticides that have been associated with Parkinson’s disease as either P-gp substrates or 
inhibitors and found that only rotenone stimulated P-gp mediated ATPase activity. Our 
data suggest that  diazinon, dieldrin, endosulfan, maneb, and MPP+ are not P-gp 
substrates or inhibitors. Further investigation is needed to understand the role of P-gp 
transport in rotenone disposition and whether transport at the blood-brain-barrier is 
altered in people with ABCB1 genetic variants.  
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3.1.  INTRODUCTION 
P-glycoprotein (P-gp) is a drug transporter that effluxes a diverse array of 
xenobiotics in healthy tissues throughout the body including the intestine, liver, kidney, 
and the blood-brain-barrier (BBB) [as reviewed in (Cascorbi, 2011; Giacomini, 1997; 
Giacomini et al., 2010; Lin and Yamazaki, 2003a; Lin and Yamazaki, 2003b; Schinkel, 
1997; Sharom, 2006; Sharom, 2011)]. P-gp is a member of the ATP-binding cassette 
(ABC) superfamily of transporters and is encoded by the multidrug resistance gene 
ABCB1 (also known as MDR1). The role of P-gp in the disposition of drugs is well 
known. Little has been described, however, regarding the role of P-gp in toxicant 
disposition.  
P-gp has also been associated with a number of diseases, including the 
neurodegenerative Parkinson’s disease (Bartels et al., 2008a; Drozdzik et al., 2003; 
Dutheil et al., 2010; Furuno et al., 2002; Le Couteur et al., 2001; Lee et al., 2004; Lee and 
Bendayan, 2004; Tan et al., 2005; Tan et al., 2004; Vautier and Fernandez, 2009; 
Westerlund et al., 2009; Westerlund et al., 2008). Pharmacogenomic studies have 
described an association between ABCB1 genetic variation and Parkinson’s disease, 
specifically with three single nucleotide polymorphisms (SNPs): 1236C>T, 2677G>T/A, 
and 3435C>T. A mechanism for this association is not known, but one possibility is that 
ABCB1 SNPs lead to decreased P-gp transport of neurotoxic xenobiotics at the blood-
brain barrier and increased brain accumulation. 
Environmental exposure to neurotoxicants has long been known as a risk factor 
for Parkinson’s disease (Bonnet and Houeto, 1999; Gatto et al., 2009; Langston et al., 
1984; Semchuk et al., 1992; Steece-Collier et al., 2002). One of the first discoveries of 
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environmental risk factor was 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 
MPTP is converted to 1-methyl-4-phenyl-4-phenylpyridinium ion (MPP+) in the brain 
and results in a parkinsonian state (Langston et al., 1983; Langston et al., 1984). MPP+ 
has been used as a pesticide under the name cyperquat. Several other pesticides have also 
been associated with an increased risk to Parkinson’s disease including paraquat, 
diazinon, dieldrin, endosulfan, maneb, MPP+ and rotenone. Epidemiological evidence 
and in vitro and animal toxicity models have demonstrated the association of these 
pesticides with Parkinson’s disease (Bradbury et al., 1986; Costello et al., 2009; Dhillon 
et al., 2008; Firestone et al., 2005; Fleming et al., 1994; Gao et al., 2002; Gatto et al., 
2009; Hatcher et al., 2007; Jia and Misra, 2007a; Jia and Misra, 2007b; Kanthasamy et 
al., 2008; Langston et al., 1984; Li et al., 2005a; Liou et al., 1997; Richardson et al., 
2006; Sharma et al., 2010; Slotkin and Seidler, 2011; Sonsalla et al., 2008; Tanner et al., 
2011; Thiffault et al., 2000; Uversky, 2004; Uversky et al., 2001; Wang et al., 2006; 
Weisskopf et al., 2010).  
P-gp plays a significant role in protecting the brain from toxic substances 
circulating in the brain, but it id uncertain if this is the role for P-gp in Parkinson’s 
disease. While not associated with Parkinson’s disease, the role of P-gp transport in the 
disposition of the neurotoxic pesticide ivermectin has been shown (Edwards, 2003; 
Mealey et al., 2003; Nelson et al., 2003; Rose et al., 1998; Roulet et al., 2003; Schinkel et 
al., 1994). This discovery was made serendipitously in knockout mdr1a(-/-) mice that were 
treated with ivermectin to combat a mite infestation. The majority of the mdr1a(-/-) mice 
died of neurotoxicity and it was determined that these mice had a 88-fold increase in 
ivermectin brain accumulation compared to wild-type mice (Edwards, 2003; Schinkel et 
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al., 1994). The case of ivermectin provides a rationale for P-gp in the transport of other 
pesticides. Although there is currently limited evidence for P-gp transport of the 
pesticides associated with Parkinson’s disease. 
 Recently, we have determined that P-gp does not mediate in vitro or in vivo 
paraquat disposition (Chapter 2). Several studies have also reported that MPP+ is not a P-
gp substrate (Martel and Azevedo, 2003; Martel et al., 2001). Maneb and rotenone have 
not been evaluated as P-gp substrates or inhibitors. There are conflicting reports on the P-
gp transport of the other pesticides diazinon, dieldrin, and endosulfan. (Bain and 
LeBlanc, 1996; Bircsak et al., 2012; Lecoeur et al., 2006; Pivcevic and Zaja, 2006). One 
report found that diazinon was transported by P-gp and also induced P-gp expression 
(Lecoeur et al., 2006), while another found only minimal P-gp inhibition relative to the 
known inhibitor verapamil (Pivcevic and Zaja, 2006). Other studies have found that 
neither dieldrin nor endosulfan were P-gp substrates, and that endosulfan, but not 
dieldrin, was capable of inhibiting P-gp (Bain and LeBlanc, 1996; Bircsak et al., 2012). 
Another study, however, observed resistance to endosulfan in P-gp expressing cells and 
concluded it was a P-gp substrate (Bain and LeBlanc, 1996), although this study did not 
confirm these findings with a known P-gp inhibitor to ensure the effect was specific to P-
gp.  
It is clear that there are contradictory reports in the literature regarding P-gp 
transport of pesticides. Currently, there is wide agreement that a reliable strategy for the 
evaluation of substrates and inhibitors of drug transporters should integrate multiple 
transport models. One challenge in interpreting previous studies that evaluated pesticides 
as P-gp substrates or inhibitors is that these studies relied on one in vitro transport model. 
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Relying on only one model can lead to false negative or false positive results that may 
vary from model to model. (Brouwer et al., 2013; Feng et al., 2008; Giacomini et al., 
2010; Polli et al., 2001). Therefore, in order to overcome some of the challenges of 
previous studies, we have used a combination of in vitro models of P-gp transport. Our 
goals are to systematically screen the Parkinson’s disease associated pesticides using a 
combination of models.  
The goals of this study were to systematically evaluate P-gp-mediated transport of 
the major pesticides that have been linked to Parkinson’s disease: diazinon, dieldrin, 
endosulfan, maneb, MPP+, and rotenone. We have screened each compound using three 
models: 1) a xenobiotic-stimulated ATPase assay in P-gp expressing membranes, 2) a 
cytotoxic sensitivity assay in LLC-PK1 recombinant cell lines, expressing either 
ABCB1/MDR1 or an empty vector, and 3) inhibition of intracellular of rhodamine-123 
(R123) accumulation. This study is the first comprehensive investigation of P-gp-
mediated transport of the major pesticides associated with Parkinson’s disease. 
 
3.2.  MATERIALS AND METHODS 
3.2.1.  Chemicals 
 Diazinon, dieldrin, endosulfan, maneb, MPP+, rotenone, ivermectin, doxorubicin, 
colchicine, verapamil, R123, and cyclosporine were purchased from Sigma-Aldrich 
Chemical Company (St. Louis, MO). GF120918, [N-(4-[2-(1,2,3,4-tetrahydro-6,7-
dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine 
carboxamide] was kindly provided by GlaxoSmithKline (Research Triangle Park, NC). 
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3.2.2.  ATPase Activity  
Stimulation of ATPase activity was measured using SB MDR1/P-gp Sf9 ATPase 
Membranes (SOLVO Biotechnology, Budaors, Hungary) as previously described 
(Chapter 2). ATPase activity in the presence of xenobiotics was estimated by measuring 
the release of inorganic phosphate (Pi) in a colorimetric reaction; and xenobiotic-
stimulated ATPase activity was determined as the difference in Pi liberation measured in 
the absence or presence of 1.2 mM sodium orthovanadate (a non-specific ATPase 
inhibitor). P-gp membranes were incubated with either diazinon, dieldrin, endosulfan, 
maneb, MPP+, rotenone, ivermectin, or the known P-gp substrate verapamil over a 
concentration range of 0.05-100 µM. Michaelis-Menten parameters (Vmax and Km) were 
estimated using a nonlinear regression Michaelis-Menten least squares model fit on Prism 
5.0 software (GraphPad, San Diego, CA). 
 
3.2.3.  Cell Culture 
LLC-PK1 vector cells (LLC-vector) and recombinant MDR1 cells (LLC-MDR1-
WT), generously provided by Michael M. Gottesman in the Laboratory of Cell Biology at 
the National Cancer Institute (Bethesda, MD), were cultured in complete Media 199 
(Mediatech, Manassas, VA) supplemented with 3% (v/v) fetal bovine serum (FBS) 
(Mediatech), 1% (v/v) L-glutamine (Mediatech), 1% (v/v) penicillin/streptomycin 
(Mediatech), and 1% (v/v) geneticin (Life Technologies, Carlsbad, CA); and grown at 
37°C in the presence of 5% CO2.  
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3.2.4.  Cytotoxic Sensitivity  
Sensitivity to cytotoxic agents was evaluated in LLC-vector and LLC-MDR1-WT 
cells as previously described (Chapter 2). Cells were treated with pesticides over a wide 
concentration range: diazinon (0.3-1000 µM), dieldrin (2.0-1000 µM), endosulfan (0.4-
100 µM), maneb (0.7-100 µM), MPP+ (0.5-3000 µM), rotenone (0.7-5000 nM), and 
ivermectin (0.4-20 µM). P-gp substrates doxorubicin (0.05 nM - 250 µM), and colchicine 
(0.01-50,000 µM) were used as positive controls. Inhibition was performed at 0.5 µM 
GF120918 and 10 µM verapamil. Compounds were evaluated in triplicate. Viability was 
estimated as the effective concentration necessary for 50% cell death (EC50) based on a 
nonlinear regression log (agonist) vs. response variable slope least squares model fit 
using Prism 5.0 software.  
 
3.2.5.  Intracellular Accumulation  
Inhibition of intracellular accumulation of the P-gp substrate, R123, was 
evaluated in LLC-vector and LLC-MDR1-WT cells as previously described (Woodahl et 
al., 2004) (Chapter 2). Cells were incubated in 5 µM R123 with and without inhibitors in 
serum-free Media 199 at 37°C and then allowed to efflux in the presence of inhibitor in 
complete Media 199. Flow cytometry was used to evaluate intracellular R123 over a 
range of pesticide concentrations: diazinon (7.0-500 µM), dieldrin (3.0-200 µM), 
endosulfan (3.0-200 µM), maneb (0.1-500 µM), MPP+ (1.0-1000 µM), rotenone (0.1-500 
µM), and ivermectin (0.05-50 µM). Known P-gp inhibitors were used as positive 
controls: GF120918 (0.78-1000 nM), cyclosporine (0.1-100 µM), and verapamil (0.1-500 
µM). Samples were run in triplicate. Immediately prior to flow cytometry, 4',6-
diamidino-2-phenylindole (DAPI) was added to the cells as a measure of cell viability. 
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Inhibition was estimated as the inhibitor concentration necessary for 50% inhibition 
(IC50) based on a nonlinear regression log (inhibitor) vs. normalized response variable 
slope least squares model fit on Prism 5.0 software. 
 
 
3.2.6.  Statistical Analysis  
Student’s one- or two-tailed t test was used to determine differences between two 
sets of data. An extra sum of squares F-test was utilized to compare individual parameters 
for the cytotoxic sensitiviy assay. The null hypothesis was that the EC50 estimates are the 
same within a cell type between xenobiotic treatment group alone and in the presence of 
a P-gp inhibitor, and the null hypothesis was only rejected if the inhibitor decreased 
cytotoxic resistance. For all analyses, p-values of < 0.05 were considered statistically 
significant. 
 
3.3.  RESULTS 
  Diazinon, dieldrin, endosulfan, maneb, MPP+, and ivermectin, failed to stimulate 
ATPase activity above the level of the orthovanadate-sensitive control (14.5 ± 1.0 nmol 
Pi/min/mg protein). This was similar to our observation that paraquat does not stimulated 
ATPase activity in P-gp membranes (Chapter 2). Rotenone, however, stimulated ATPase 
activity with Vmax and Km parameters of 32.4 ± 1.64 nmol Pi/min/mg protein and 1.78 ± 
0.55 µM, respectively (Figure 3.1., page 78). This compared to the P-gp substrate 
verapamil with Vmax and Km parameters of 48.4 ± 2.58 nmol Pi/min/mg protein and 2.54 
± 0.68, respectively. 
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Dose–response curves of cytotoxicity to diazinon, dieldrin, endosulfan, maneb, 
MPP+, rotenone, and ivermectin for LLC-vector and LLC-MDR1-WT cells are presented 
in Figures 3.2.-3.10., pages 79 -87. EC50 values are presented in Table 3.1., page 77. 
When compared to LLC-vector cells, LLC-MDR1-WT cells exhibit significantly 
increased resistance to the positive controls doxorubicin and colchicine as expected 
(Figure 3.9. and 3.10., pages 86-87). Additionally, the P-gp inhibitors GF120918 and 
verapamil reversed cellular resistance in LLC-MDR1-WT cells. None of the tested 
pesticides showed differential cytotoxicity mediated by P-gp in this model that was 
sensitive to both P-gp inhibitors GF120918 and verapamil (Figures 3.2.-3.8., pages 79-
85). While there was modest increase in resistance to dieldrin, maneb, MPP+, and 
rotenone in LLC-MDR1-WT cells compared to LLC-vector cells, the P-gp inhibitor 
GF120918 did not reverse the resistance in LLC-MDR1-WT. We have also found a 
similar observation in cellular sensitivity to paraquat (Chapter 2). Verapamil reduced the 
cytotoxic sensitivity of LLC-MDR1-WT cells to dieldrin, MPP+, and rotenone, however, 
GF120918 was unable to reproduce this effect. There were no cellular differences in the 
resistance to endosulfan and ivermectin in LLC-MDR1-WT cells. Together, these data 
indicate that in this model of cytotoxic sensitivity, P-gp possibly mediates cellular 
resistance to dieldrin, MPP+, and rotenone. 
 The pesticides were also evaluated as inhibitors of P-gp by their ability to inhibit 
R123 efflux in LLC-vector and LLC-MDR1-WT cells compared to known P-gp 
inhibitors GF120918, verapamil, and cyclosporine (Figure 3.11., page 88). There was no 
effect of the pesticides or known P-gp inhibitors had any effect on intracellular 
accumulation of R123 in LLC-vector cells (data not shown). Diazinon, dieldrin, 
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endosulfan, maneb, MPP+, and rotenone did not inhibit R123 accumulation in P-gp-
expressing cells even at the highest concentrations. We also found previously that 
paraquat does not inhibit R123 efflux (Chapter 2). Ivermectin inhibited R123 with an IC50 
value of 0.252 ± 0.048 µM compared to known inhibitors GF120918, verapamil, and 
cyclosporine with IC50 values of 22.9 ± 1.92 nM, 1.98 ± 0.12 µM, and 1.39 ± 0.07 µM, 
respectively.   
 
3.4.  DISCUSSION 
We have screened for P-gp transport of the pesticides diazinon, dieldrin, 
endosulfan, maneb, MPP+, and rotenone using a combination of in vitro models to 
investigate the relationship between ABCB1 genetic variation and Parkinson’s disease 
risk. Of these pesticides, we determined that only rotenone is a substrate of P-gp. We 
determined that diazinon, dieldrin, endosulfan, maneb, and MPP+ are not P-gp substrates 
or inhibitors. This is consistent with our previous work with the Parkinson’s disease- 
associated pesticide paraquat (Chapter 2).  
ABCB1 pharmacogenomics have been associated with altered susceptibility to 
Parkinson’s disease (Bartels et al., 2008a; Drozdzik et al., 2003; Dutheil et al., 2010; 
Furuno et al., 2002; Le Couteur et al., 2001; Lee et al., 2004; Lee and Bendayan, 2004; 
Tan et al., 2005; Tan et al., 2004; Vautier and Fernandez, 2009; Westerlund et al., 2009; 
Westerlund et al., 2008). While these studies provide evidence for a role of P-gp in 
Parkinson’s disease, the mechanism is unclear. One hypothesis is that decreased P-gp 
activity at the BBB results in increased brain accumulation of neurotoxicants and an 
increased incidence of Parkinson’s disease. Neurotoxic pesticides are known risk factors 
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for the development of Parkinson’s disease (Bradbury et al., 1986; Costello et al., 2009; 
Dhillon et al., 2008; Firestone et al., 2005; Fleming et al., 1994; Gao et al., 2002; Gatto et 
al., 2009; Hatcher et al., 2007; Jia and Misra, 2007a; Jia and Misra, 2007b; Kanthasamy 
et al., 2008; Langston et al., 1984; Li et al., 2005a; Liou et al., 1997; Richardson et al., 
2006; Sharma et al., 2010; Slotkin and Seidler, 2011; Sonsalla et al., 2008; Tanner et al., 
2011; Thiffault et al., 2000; Uversky, 2004; Uversky et al., 2001; Wang et al., 2006; 
Weisskopf et al., 2010). There has not, however, been a systematic evaluation of P-gp 
transport of the pesticides associated with Parkinson’s disease until now.  
An important consideration when evaluating compounds as substrates or 
inhibitors of membrane transporters is that multiple models of in vitro transport are 
required and each model has its own advantages and limitations (Brouwer et al., 2013; 
Feng et al., 2008; Giacomini et al., 2010; Polli et al., 2001). Unfortunately, the 
information that exists regarding P-gp transport of pesticides associated with Parkinson’s 
disease is incomplete with most studies utilizing one or at most two in vitro models. The 
pesticides diazinon, dieldrin, endosulfan, maneb, MPP+, and rotenone must be evaluated 
as substrates or inhibitors of P-gp prior to moving forward with understanding the 
mechanism responsible for the relationship between genetic variation in ABCB1 and 
Parkinson’s disease risk. An important aspect of our work was to utilize three different in 
vitro P-gp transport assays: xenobiotic-stimulated ATPase activity, cytotoxic sensitivity, 
and inhibition of R123 intracellular accumulation.  
The ATPase assay identified only rotenone as capable of stimulating ATPase 
activity in P-gp-expressing membranes. Diazinon, dieldrin, endosulfan, ivermectin, 
maneb, and MPP+ did not stimulate ATPase activity above the level of the 
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orthovanadate-sensitive control, which is similar to our previous observations with 
paraquat (Chapter 2). Therefore, it is likely that rotenone is a P-gp substrate. 
LLC-PK1 cells have many features that make them the gold standard cell model 
of transport, mainly that they form polarized monolayers, have low endogenous 
transporter expression, and express tight junction proteins. However, one of the 
drawbacks of using LLC-PK1 recombinant cell lines is that there may be other changes 
induced in the cells in addition to the expression of P-gp. Therefore, it is important to not 
only have a vector control cell line but also use a P-gp inhibitor to confirm the results. 
For example, a dramatic increase in resistance was observed in LLC-MDR1-WT cells 
compared to LLC-vector cells for known P-gp substrates, doxorubicin and colchicine, 
and this resistance was reversed in the presence of the P-gp inhibitors GF120918 and 
verapamil. When screening the pesticides diazinon, dieldrin, maneb, MPP+, and 
rotenone, there was a modest increase in resistance in LLC-MDR1-WT cells, however 
the P-gp inhibitor GF120918 did not have any effect on the resistance. The P-gp inhibitor 
verapamil reduced the cytotoxic sensitivity of LLC-MDR1-WT cells to dieldrin, MPP+, 
and rotenone, which suggests that these pesticides maybe P-gp substrates, however, 
GF120918 was unable to reproduce this effect. However, combining our previous 
observations with rotenone in the ATPase assay with the reduction in cytotoxic 
sensitivity in LLC-MDR1-WT cells when co-treated with verapamil makes a strong case 
for rotenone as a likely P-gp substrate. The results from our cytotoxic sensitivity assay 
clearly demonstrate the importance of using of P-gp inhibitors to interpret results in P-gp 
transfected cell lines.  
	  
	  
73	  
	  
In addition to screening the pesticides as potential substrates of P-gp, we 
evaluated them as potential inhibitors of P-gp. Ivermectin was able to completely inhibit 
R123 efflux, however, none of the pesticides associated with Parkinson’s disease were 
able to inhibit R123 efflux in LLC-MDR1 cells, even at high concentrations. 
Our study is the first to evaluate the P-gp transport of maneb and rotenone, both 
of which have been highly associated with Parkinson’s disease risk. We observed no 
evidence for maneb as a P-gp substrate or inhibitor in any of the in vitro assays. 
Rotenone, however, stimulated ATPase activity with a Km lower than that for the known 
P-gp substrate verapamil. This suggests that rotenone may bind with higher affinity to P-
gp than verapamil. We also observed differential cytotoxicity to rotenone in LLC-MDR1-
WT when co-treated with verapamil, which suggests that rotenone was a substrate in both 
the ATPase assay and the the cytotoxic sensitivity assay. Rotenone highlights the value in 
using multiple models to assess P-gp transport, and suggests a role for P-gp in rotenone 
transport.  Further work is needed to determine if P-gp limits brain distribution of 
rotenone and whether alteration of P-gp transport at the BBB due to ABCB1 genetic 
variation would alter rotenone brain accumulation.  
Although dieldrin has not previously been evaluated as a P-gp substrate, our work 
is consistent with previous reports that dieldrin does not inhibit P-gp (Bain and LeBlanc, 
1996). Our data conflicts, however, with previous reports for endosulfan and diazinon but 
such reports have been inconsistent and without appropriate controls (Bain and LeBlanc, 
1996; Bircsak et al., 2012; Pivcevic and Zaja, 2006). Endosulfan was previously 
classified as a substrate in a study that found that B16/hMDR1 cells were 2.5-fold more 
resistance to endosulfan compared with B16/F10 cells (Bain and LeBlanc, 1996). This 
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study, however, did not use a P-gp inhibitor to confirm their findings, which we have 
discussed previously is critical when interpreting results from cytotoxic assays. In 
contrast we saw no change in resistance to endosulfan in P-gp expressing cells. 
Additionally, one report suggested incomplete inhibition of P-gp by endosulfan (Pivcevic 
and Zaja, 2006) and another reporting an IC50 of 33.6 µM (Bircsak et al., 2012). We did 
not observe inhibition of P-gp by endosulfan, however, even at concentrations up to 200 
µM. Diazinon has been reported previously to be a substrate and inducer of P-gp in 
transepithelial studies in Caco-2 cells (Lecoeur et al., 2006), although the permeability 
ratios they estimated were low (<3) which suggests that while there is directional 
transport of diazinion in the basolateral-to-apical direction, it is much less than what is 
seen for canonical P-gp substrates. Diazinon was also shown to incompletely inhibit of P-
gp using recombinant cells (Pivcevic and Zaja, 2006), although we found no inhibition of 
P-gp up to 500 µM. Since it is critical to utilize multiple models of transport to evaluate 
P-gp, our approach of screening pesticides with three in vitro models provides confidence 
in our observations regarding the P-gp transport of pesticides associated with Parkinson’s 
disease.  
Although not linked to Parkinson’s disease, we also screened the pesticide 
ivermectin since its brain disposition as a result of P-gp transport has been well 
documented (Edwards, 2003; Mealey et al., 2003; Nelson et al., 2003; Rose et al., 1998; 
Roulet et al., 2003; Schinkel et al., 1994). We found that ivermectin is a good inhibitor of 
P-gp, but did not stimulate ATPase activity or contribute to differential cytotoxicity in P-
gp expressing cells indicating that it is not a P-gp substrate. The initial studies of 
ivermectin as a neurotoxic P-gp substrate are from studies in mdr1a knock-out mice that 
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were much more sensitive (100-fold) and had increased brain uptake (87-fold) of 
ivermectin (Schinkel et al., 1994). In addition, collie dogs with a deletion of the mdr1 
gene are also extremely sensitive to the neurotoxic effects of ivermectin (Edwards, 2003; 
Mealey et al., 2001; Mealey et al., 2003; Nelson et al., 2003; Roulet et al., 2003). To our 
knowledge, there has been no direct in vitro investigation of ivermectin as a P-gp 
substrate, however, our finding was surprising given the previous in vivo observations in 
mdr knockout or deficient animals. Our observation reinforces the importance of using 
multiple models when evaluating compounds as substrates or inhibitors P-gp.  
 
3.5.  CONCLUSIONS 
In summary, using three different in vitro transport models we have screened the 
primary pesticides that have been linked to Parkinson’s disease as P-gp substrates and 
inhibitors. We have demonstrated that diazinon, endosulfan, and maneb are not substrates 
or inhibitors of P-gp. Interestingly, we have shown for the first time that rotenone maybe 
a P-gp substrate by its ability to stimulate P-gp mediated ATPase activity as well as 
display reduced cytotoxic sensitivity in LLC-MDR1-WT cells when co-treated with 
verapamil. Although dieldrin and MPP+ also displayed reduced cytotoxic sensitivity in 
LLC-MDR1-WT cells when co-treated with verapamil, they did not activate ATPase 
activity or inhibit R123 efflux, suggesting that more clarification is needed to verify the 
results of the cytotoxic sensitivity assay.  ABCB1 pharmacogenomic studies have shown 
evidence for a role of P-gp in the development of Parkinson’s disease. It is clear from our 
data, however, that with the possible exceptions of dieldrin, MPP+, and rotenone, 
differential P-gp transport of many of the pesticides that have been associated with 
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Parkinson’s disease is likely not the cause. P-gp transport of dieldrin, MPP+, and 
rotenone at the BBB, and alterations to transport due to ABCB1 genetic variation, 
requires further investigation. 
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Table 3.1. Pesticide Cytotoxicity in LLC-vector and LLC-MDR1-WT Cells 
 EC50 Values (95% Confidence Interval) 
LLC-PK1 Cells LLC-vector LLC-MDR1-WT 
Diazinon (µM) 1790 (n.d.) 384 (273 – 540) 
Diazinon (µM)  + GF120918 132 (67 – 261) 414 (161 – 1070) 
Diazinon (µM) + Verapamil 494 (73 – 3330) 380 (157 – 922) 
Dieldrin (µM) 51.4 (40.7 – 65.0) 75.4 (62.1 – 91.7) 
Dieldrin (µM) + GF120918 38.2 (27.9 – 52.2) 70.7 (56.8 – 87.9) 
Dieldrin (µM) + Verapamil 33.2 (27.3 – 40.2)a 40.0 (30.7 – 52.0)c 
Endosulfan (µM) 14.0 (10.0 – 19.5) 19.4 (12.4 – 30.4) 
Endosulfan (µM) + GF120918 17.4 (11.5 – 26.3) 40.7 (16.7 – 99.0) 
Endosulfan (µM) + Verapamil 8.80 (5.33 – 14.53) 16.7 (10.4 – 27.0) 
Maneb (µM) 49.1 (n.d.) 39.36 (n.d.) 
Maneb (µM) + GF120918 24.6 (13.8 – 43.9) 36.4 (31.5 – 42.2) 
Maneb (µM) + Verapamil 414.1 (n.d.) 37.3 (33.2 – 41.8) 
MPP+ (µM) 27.1 (16.7 – 44.0) 418 (169 – 1040) 
MPP+ (µM) + GF120918 84.9 (35.6 – 202.5) 566 (287 – 1120) 
MPP+ (µM) + Verapamil 31.9 (18.1 – 56.4) 69.0 (39.3 – 121.1)b 
Rotenone (nM) 12.5 (7.6 – 20.3) 27.7 (21.3 – 36.1) 
Rotenone (nM) + GF120918 17.4 (11.4 -26.6) 35.0 (22.2 – 55.2) 
Rotenone (nM) + Verapamil 5.89 (3.83 – 9.05) 7.25 (4.29 – 12.23)b 
Ivermectin (µM) 4.86 (4.51 – 5.23) 4.04 (3.75 – 4.36) 
Ivermectin (µM) + GF120918 5.76 (5.23 – 6.23) 4.59 (3.94 – 5.35) 
Ivermectin (µM) + Verapamil 3.59 (2.66 – 4.86)a 4.25 (4.02 – 4.50) 
Doxorubicin (nM) 34.2 (13.7 – 85.6) 1978 (1015-3850) 
Doxorubicin (nM) + GF120918 24.8 (12.0 – 51.3) 8.06 (1.32 – 49.2)c 
Doxorubicin (nM) + Verapamil 43.4 (12.0 – 155.9) 268 (90.7 – 98.6)c 
Colchicine (µM) 13.3 (n.d.) 645 (467 – 892) 
Colchicine (µM) + GF120918 12.6 (10.8 – 14.5) 17.5 (12.0 – 25.4)c 
Colchicine (µM) + Verapamil 12.8 (n.d.) 179 (117 – 273)c 
Significant differences within a cell type between xenobiotic treatment group alone and 
in the presence of a P-gp inhibitor; p < 0.05a, p < 0.005b, p < 0.0005c. 
* n.d.: not determined. Nonlinear regression was unable to estimate confidence intervals. 
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Figure 3.1. Rotenone Stimulated ATPase Activity in SB MDR1/P-gp Sf9 
Membranes. P-gp membranes were incubated with either rotenone (open triangle) or the 
known P-gp substrate verapamil (closed circle) over a concentration range of 0.05 - 100 
µM. ATPase activity was determined as the difference in Pi liberation measured in the 
absence or presence of 1.2 mM sodium orthovanadate (verapamil + sodium 
orthovanadate (open square).  
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3.2.a LLC-vector     
 
3.2.b LLC-MDR1-WT 
 
 
Figure 3.2. Cytotoxic Sensitivity to Diazinon in LLC-vector and LLC-MDR1-WT. 
Cells were treated with diazinon (a-b, concentration range of 0.3-1000 µM), (square, 
solid line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
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3.3.a LLC-vector     
 
3.3.b LLC-MDR1-WT 
 
Figure 3.3. Cytotoxic Sensitivity to Dieldrin in LLC-vector and LLC-MDR1-WT. 
Cells were treated with dieldrin (a-b, concentration range of 2.0-1000 µM), (square, solid 
line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
 
1 10 100 1000
0
50
100
150
Dieldrin Concentration (µM)
%
 V
ia
bl
e 
C
el
ls
1 10 100 1000
0
50
100
150
Dieldrin Concentration (µM)
%
 V
ia
bl
e 
C
el
ls
	  
	  
81	  
	  
3.4.a LLC-vector     
 
3.4.b LLC-MDR1-WT 
 
Figure 3.4. Cytotoxic Sensitivity to Endosulfan in LLC-vector and LLC-MDR1-WT. 
Cells were treated with endosulfan (a-b, concentration range of 0.4-100 µM), (square, 
solid line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
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3.5.a LLC-vector     
 
3.5.b LLC-MDR1-WT 
 
Figure 3.5. Cytotoxic Sensitivity to Maneb in LLC-vector and LLC-MDR1-WT. 
Cells were treated with maneb (a-b, concentration range of 0.7-100 µM), (square, solid 
line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
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3.6.a LLC-vector     
 
3.6.b LLC-MDR1-WT 
 
Figure 3.6. Cytotoxic Sensitivity to MPP+ in LLC-vector and LLC-MDR1-WT. 
Cells were treated with MPP+ (a-b, concentration range of 0.5-3000 µM), (square, solid 
line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
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3.7.a LLC-vector     
 
3.7.b LLC-MDR1-WT 
 
Figure 3.7. Cytotoxic Sensitivity to Rotenone in LLC-vector and LLC-MDR1-WT. 
Cells were treated with rotenone (a-b, concentration range of 0.7-5000 nM), (square, 
solid line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
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3.8.a LLC-vector     
 
3.8.b LLC-MDR1-WT 
 
Figure 3.8. Cytotoxic Sensitivity to Ivermectin in LLC-vector and LLC-MDR1-WT. 
Cells were treated with ivermectin (a-b, concentration range of 0.4-20 µM), (square, solid 
line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). 
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3.9.a LLC-vector     
 
3.9.b LLC-MDR1-WT 
 
Figure 3.9. Cytotoxic Sensitivity to Doxorubicin in LLC-vector and LLC-MDR1-
WT. Cells were treated with doxorubicin (a-b, concentration range of 0.05 nM - 250 
µM), (square, solid line). Cell viability was evaluated using the CellTiter-Glo® Cell 
Viability Assay. Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) 
and 10 µM verapamil (circle, dotted line). Doxorubicin has been reported previously 
(Chapter 2).  
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3.10.a LLC-vector     
 
3.10.b LLC-MDR1-WT 
 
Figure 3.10. Cytotoxic Sensitivity to Colchicine in LLC-vector and LLC-MDR1-WT. 
Cells were treated with colchicine (a-b, concentration range of 0.01-50,000 µM), (square, 
solid line). Cell viability was evaluated using the CellTiter-Glo® Cell Viability Assay. 
Inhibition was performed at 0.5 µM GF120918 (triangle, dashed line) and 10 µM 
verapamil (circle, dotted line). Colchicine has been reported previously (Chapter 2). 
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Figure 3.11. Inhibition of P-gp Transport of Rhodamine-123 by Pesticides. Data are 
presented as a percent of rhodamine-123 inhibition and values are mean ± SEM. Tested 
compounds are diazinon (closed circle), dieldrin (closed hexagon), endosulfan (open 
circle), maneb (closed square), MPP+ (closed diamond), rotenone (open triangle), 
paraquat (open triangle), ivermectin (open square), GF120918 (closed star), verapamil 
(open diamond), and cyclosporine (closed triangle). Paraquat, GF120918, verapamil, and 
cyclosporine data has been reported previously (Chapter 2). 
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CHAPTER 4 
 
 
 
PARAQUAT EXPOSURE DOES NOT ALTER DOPAMINE 
CONCENTRATIONS OR SPONTANEOUS MOTOR FUNCTION  
IN C57BL/6J OR FVB MICE 
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ABSTRACT 
 Paraquat is an herbicide that has been studied as a risk factor for Parkinson’s 
disease. Although some evidence suggests that paraquat exposure in mice results in death 
to the dopaminergic neurons in the substantia nigra and impaired motor function, there is 
also a growing body of evidence suggesting no relationship between paraquat and nigral 
damage. In an attempt to elucidate the discrepancies in these reports, the effects of 
chronic paraquat exposure on spontaneous motor activity, oxidative stress in the striatum, 
and concentrations of dopamine (DA) and its primary metabolites in the striatum, were 
evaluated following administration of the most common sub-lethal dosing regimen of 10 
mg/kg paraquat twice a week for 3 or 4 weeks in C57BL/6J and FVB male mice. 
Spontaneous motor activity was evaluated using the open-field test before and after 
treatment with saline or paraquat. Oxidative stress was measured using the OxyBlotTM 
Protein Oxidation detection kit. DA, and its metabolites were measured using reverse-
phase high performance liquid chromatography with electrochemical detection. Chronic 
paraquat treatment for 3 or 4 weeks did not result in any change in spontaneous motor 
activity or oxidative stress between paraquat and saline treated controls. In addition, 
paraquat failed to decrease DA or increase DA turnover in the striatum. Our data 
demonstrate that chronic administration of paraquat does not induce motor impairment, 
oxidative stress, or dopaminergic loss in the striatum in either the classic C57BL/6J 
mouse model for Parkinson’s disease or FVB mice using the current exposure paradigm. 
A reliable and consistent mouse model for induction of neurotoxicity following paraquat 
exposure is needed to evaluate paraquat as a risk factor for Parkinson’s disease in 
humans. 
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4.1.  INTRODUCTION 
Paraquat dichloride, or methyl viologen, is an herbicide that has been studied as a 
Parkinson’s disease-inducing neurotoxicant (Costello et al., 2009; Dinis-Oliveira et al., 
2006b; Liou et al., 1997; Tanner et al., 2011; Tomenson and Campbell, 2011). The 
degree of dopaminergic cell death following paraquat exposure is contradictory, however, 
in published reports in the literature. Conversely, the parkinsonian neurotoxicant 1-
methyl-4-phenyl-1,2,3,5-tetrahydropyridine (MPTP), which is chemically similar to 
paraquat, consistently reduces levels of dopamine (DA) and its primary metabolites, 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and induces motor 
dysfunction in C57BL/6J mice (Bradbury et al., 1986; Breckenridge et al., 2013; 
Cardozo-Pelaez et al., 2012; Gibrat et al., 2009; Langston et al., 1984; Luchtman et al., 
2009; Przedborski et al., 1996). Criticisms regarding the ability of paraquat to induce 
Parkinson’s disease include its polar charge, limited absorption, and poor BBB 
penetration (Koller, 1986). Others have questioned the methods researchers have used to 
study the mechanisms of paraquat-induced dopaminergic toxicity as well as questioned 
the rationale of the chemical similarity between paraquat and MPTP as a justification for 
paraquat being a Parkinson’s disease-related neurotoxicant (Miller, 2007; Ramachandiran 
et al., 2007). 
Epidemiological evidence has associated paraquat exposure with Parkinson’s 
disease risk (Hertzman et al., 1990; Liou et al., 1997; Semchuk et al., 1992; Tanner et al., 
2011; Tanner et al., 2009; Wang et al., 2011). Researchers have shown that paraquat 
induces toxicity associated with the progression of Parkinson’s disease due to increased 
oxidative stress and a loss of dopaminergic neurons in the substantia nigra in rodents. 
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Specifically, researchers have described a reduction in the number of tyrosine 
hydroxylase positive (TH+) neurons in the substantia nigra pars compacta (SNpc) 
following intraperitoneally (i.p.) administered paraquat to C57BL/6J mice (Brown et al., 
2006; Jiao et al., 2012; McCormack et al., 2006). The TH enzyme catalyzes the rate-
limiting step in the synthesis of DA, and thus the amount of tyrosine-hydroxylase in a cell 
is an indirect measure of the amount of DA. Other reports suggest that DA, DOPAC, and 
HVA were decreased and DA turnover was increased in the striatum in mice following 
paraquat exposure (Li et al., 2005b; Prasad et al., 2009; Ren et al., 2009; Shepherd et al., 
2006). Measures of motor behavior have also suggested that locomotor activity is 
affected by chronic paraquat administration (Brooks et al., 1999; Li et al., 2005b; Ren et 
al., 2009).  
There is a growing body of evidence, however, that does not support previous 
findings of dopaminergic death following treatment with paraquat. The concentrations of 
DA, HVA, and DOPAC, as well as DA turnover in the striatum of C57BL/6J mice have 
been reported to be either unaffected or only marginally affected following paraquat 
exposure (Breckenridge et al., 2013; McCormack et al., 2002; Woolley et al., 1989). 
Locomotor activity has also shown to be unaffected or marginally affected following 
paraquat administration (Shepherd et al., 2006; Yang et al., 2007). Another important 
finding is that paraquat-induced SNpc neuron DA loss is highly dependent on genetic 
background as C57BL/6J mice, but not Swiss-Webster mice, are susceptible to 
dopaminergic toxicity following chronic paraquat administration (Jiao et al., 2012).  
The neurotoxicity induced by paraquat exposure as a model for Parkinson’s 
disease mice is controversial. The goal of our study was to investigate the contradictory 
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evidence regarding the death of dopaminergic neurons following chronic i.p. paraquat 
exposure following the most common non-lethal exposure paradigm. We evaluated 
neurotoxicity in two difference mouse strains: 1) in C57BL/6J mice, which are the 
standard mouse used to model Parkinson’s disease and 2) FVB mice, which have not 
previously been used as a model of Parkinson’s disease.  
 
4.2.  MATERIAL AND METHODS 
4.2.1.  Paraquat Exposure in Mice 
Male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) and FVB mice 
(Taconic Farms, Germantown, NY) between 5-7 months of age were used for all studies. 
Mice were maintained on a 12 hr light-dark cycle, housed in microisolators, and were 
given food and deionized water ad libitum. All procedures were approved by the 
University of Montana Institutional Animal Care and Use Committee. Paraquat (Sigma-
Aldrich Chemical Company, St. Louis, MO) was prepared at a concentration of 100 
mg/ml and injected at a volume based on individual mouse weight (<100 µl). The most 
commonly reported and sub-lethal paraquat dosing regimen was selected. Two exposures 
were given i.p. for each mouse strain: 1) 10 mg/kg, 2 times per week for 3 weeks; and 2) 
10 mg/kg, 2 times per week for 4 weeks. Control mice were treated with saline on the 
same schedule. All mice were euthanized via cervical dislocation followed by rapid 
decapitation 7 days post-injection of the final dose. During the 4 or 5 week experimental 
period, each animal was observed twice daily for mortality as well as for changes in 
appearance or behavior.  
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4.2.2.  Motor Assessment 
Motor behavior was evaluated one day prior to the first paraquat or saline 
treatment and again 1 week following the last treatment using the open field test. The 
open field test is a common measure of behavior and activity in rodents, where both the 
quality and quantity of the activity is evaluated (Hutter-Saunders et al., 2012). The tests 
were performed in a 30 cm square box, under 20 lux light intensity, and during the light 
hours of the day. The field is marked with a grid and infrared beams and video cameras 
were utilized to assess and record activity. All animals were evaluated during the same 
time frame and after a 1 hr conditioning period in which the mice were allowed to 
acclimate to the light and temperature levels in the room where the open field test is 
completed. Spontaneous motor activity was recorded using ANY-maze software 
(Stoelting, Wood Dale, IL). We measured total distance traveled, speed, time spent 
immobile, number of line crossings, number of rearings, and distance traveled from 
center over a 10 min period. Data are represented as mean ± standard deviation. 
 
4.2.3.  Oxidative Stress 
 Carbonylated protein abundance was evaluated by Western immunoblotting of 
striatum isolated following chronic paraquat administration to either C57Bl/6J or FVB 
mice. Frozen striatum was sonicated in 10 µl PBS followed by 90µl RIPA lysis buffer 
(Millipore, Billerica, MA). Following lysis samples were centrifuged for 15 min at 
10,000 g and 4°C, pellet was discarded, and the cytosolic proteins in the supernatant were 
used. Protein carbonylation was assessed by measuring the levels of carbonyl groups 
using the OxyBlot protein oxidataion detection kit (Millipore, Billerica, MA). Carbonyl 
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groups at the protein side chains were derivatized from 2,4-dinitrophenylhydrazone by 
reactions with 2,4-dinitrophenylhydrazine. Derivatized proteins were subjected to SDS-
PAGE and electro transferred to nitrocellulose membranes. Quantification analysis of 
blots was performed using Image Gauge Software (Fujifilm, Tokyo, Japan).   
 
4.2.4.  Neurochemical Analysis 
Levels of DA, DOPAC, and HVA in the striatum were measured using reverse 
phase high performance liquid chromatography (RP-HPLC) with electrochemical 
detection as previously described (Cardozo-Pelaez et al., 2005; Cardozo-Pelaez et al., 
2012; Cardozo-Pelaez et al., 1999). The index of DA turnover was calculated as 
([DOPAC + HVA]/DA). 
 
 4.2.5.  Statistical Analysis  
Student’s two-tailed t test was used to determine differences between two sets of 
data. For all analyses, p-values of < 0.05 were considered statistically significant. 
Statistical tests were performed with Graphpad Prism® statistical software (Sorrento, 
CA). 
 
4.3.  RESULTS  
 Administration of 10mg/kg paraquat i.p. 2 times a week for 3 weeks failed to 
induce oxidative stress in the striatum of either C57BL/6J or FVB mice (Figure 4.1., page 
103). In addition this dosing regimen failed to decrease concentrations of DA in the 
striatum of both the C57BL/6J and FVB mice (Figure 4.2a, page 104), and also failed to 
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increase DA turnover in the striatum of C57BL/6J mice and only modestly (1.2-fold) 
increased turnover in FVB mice (Figure 4.2b, page 104). There were differences between 
pre- and post-treatment in both the C57BL/6J and FVB mice, but the differences were 
present in both saline and paraquat treated mice. When we compare saline to paraquat 
treated animals we observe no significant differences indication to effect of paraquat 
exposure (Table 4.1., page 101). Three week chronic treatment of paraquat failed to 
induce marked neurotoxicity either by biochemical or motor behavioral measurements.  
In an attempt to replicate the reported dopaminergic toxicity in C57BL/6J mice, 
we repeated the paraquat exposure of 10 mg/kg i.p. 2 times a week and extended it for an 
additional week, for a 4 week total exposure. Administration of 10mg/kg paraquat i.p. 2 
times a week for 4 weeks failed to induce oxidative stress in the striatum of either 
C57BL/6J or FVB mice (Figure 4.3., page 105). We again did not observe any significant 
differences in the DA concentrations (Figure 4.4a, page 106) or the DA turnover (Figure 
4.4b, page 106) in either strain of mice. Similar to the 3 week exposure, there were 
differences between pre- and post-treatment in both the C57BL/6J and FVB mice in both 
saline and paraquat treated mice, but almost all differences disappeared when comparing  
saline and paraquat treatment indicating no effect on motor function following paraquat 
exposure (Table 4.2., page 102). The only significant difference between saline and 
paraquat treated mice was in time spent immobile in the FVB mice, but it was only 
observed in the pre-treatment group, indicating it was not related to paraquat exposure.  
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4.4.  DISCUSSION  
We failed to induce neurotoxicity in C57BL/6J mice via chronic administration of 
paraquat using a previously published sub-lethal exposure paradigm. We also could not 
induce neurotoxicity in FVB mice using this method. While C57BL/6J mice are routinely 
used as a model for neurodegeneration in Parkinson’s disease, FVB mice have not been 
used in such models. Neither a 3 nor 4 week treatment with 10 mg/kg i.p. paraquat 2 
times a week induced significant changes indicative of paraquat-induced dopaminergic 
dysfunction including changes in motor function, oxidative stress, DA concentrations, or 
DA turnover. The assessment and neurochemical analysis methods to test 
neurodegeneration have been validated previously with the known Parkinsonian 
neurotoxicant, MPTP (Cardozo-Pelaez et al., 2012). If paraquat caused toxicity to the 
SNpc neurons then we would expect motor dysfunction, and increase in oxidative stress, 
a decrease in DA, and an increase in DA turnover. Current literature suggests this is 
precisely the case for the known Parkinson’s disease neurotoxicant MPTP (Bradbury et 
al., 1986; Breckenridge et al., 2013; Cardozo-Pelaez et al., 2012; Gibrat et al., 2009; 
Langston et al., 1984; Luchtman et al., 2009; Przedborski et al., 1996). We did not 
observe any changes that would be associated with paraquat-induced neurodegeneration. 
Our data suggest that paraquat is not inducing neurodegeneration following chronic sub-
lethal doses of paraquat.  
Our results are consistent with previous reports of a lack of alterations in DA 
levels or DA turnover in the striatum in C57BL/6J mice (Breckenridge et al., 2013; 
McCormack et al., 2002; Woolley et al., 1989). These results are especially interesting in 
light of a recent study using a similar paraquat exposure model (10, 15, or 25 
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mg/kg/week for 1, 2, or 3 weeks) in C57BL/6J mice where they showed no difference in 
TH+ neurons, DA levels, DA turnover, or apoptotic cell death (Breckenridge et al., 2013).  
The growing body of evidence against paraquat-induced neurotoxicity is in 
contrast with other researchers who have demonstrated dopaminergic toxicity following 
chronic paraquat administration in C57BL/6J mice. Following 5 or 10 mg/kg i.p. 
administration of paraquat 2 times a week for 3 weeks in C57BL/6J mice, researchers 
observed a reduction in the number of TH+ neurons (Jiao et al., 2012; McCormack et al., 
2006). Conversely, neurotoxicity could not be induced in Swiss-Webster mice (Jiao et al., 
2012). Another study also found a reduction in the TH+ neurons following 10 mg/kg i.p. 
administration of paraquat every 2 days for a total of 10 doses, however, one of the mice 
died during the treatment (Li et al., 2005b). Staining for TH+ neurons is only an indirect 
approximate of the amount of DA in the striatum, but other researchers have also directly 
measured the loss of DA, HVA, and DOPAC in the SNpc following administration of 
paraquat (Li et al., 2005b; Prasad et al., 2009; Ren et al., 2009). However, dosing 
regimens in those studies varied widely from daily oral doses for 4 months to i.p. 
administration 2 or 3 times a week for up to 36 total doses. Motor behavior assessments 
following 10 mg/kg i.p. administration of paraquat have also suggested that spontaneous 
locomotor activity is affected (Brooks et al., 1999; Li et al., 2005b; Ren et al., 2009), but 
again these studies varied in dosing regimen ranging from daily oral doses for 4 months 
to i.p. administration once a week for 3 weeks. The lack of consistency in routes of 
administration and exposure regimens could be a possible cause of many of the 
discrepancies when comparing data. 
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Finally, to add to the complexity of chronic paraquat administration in mice, the 
Office of Research Integrity (ORI) recently reported that a former assistant professor 
committed research misconduct by fabricating stereological cell count data in a study 
regarding how pesticides, including paraquat, influence neuronal mechanisms involved in 
Parkinson’s disease (Dahlberg; Dunning, 2012).  The ORI found that the fabrication had 
been intentional and two papers were recalled, including one specifically regarding 
paraquat exposure (Rodriguez et al., 2005; Thiruchelvam et al., 2005). In addition to the 
recalled papers, the author who was cited for research misconduct has also published 
numerous papers regarding chronic paraquat administration and neurotoxicity 
(McCormack et al., 2002; Prasad et al., 2007; Thiruchelvam et al., 2000a; Thiruchelvam 
et al., 2003; Thiruchelvam et al., 2000b; Thiruchelvam et al., 2002; Winnik et al., 2009). 
This issue most certainly casts doubt on all of the work generated by this researcher 
regarding paraquat-induced neurodegeneration and highlights the need for a reliable 
parquat-exposure model.  
In addition to not inducing dopaminergic loss in the SNpc in the Parkinson’s 
disease model organism C57BL/6J mice, we were also not able to induce toxicity in FVB 
mice, which have not been studied previously. In light of our observations and previous 
reports, it is possible that paraquat induced dopaminergic dysfunction is highly dependent 
on mouse strain. In order to fully understand the role of paraquat in human toxicity and 
Parkinson’s disease risk, a standardized and reproducible model of paraquat induced 
neurotoxicity in crucial and may need to be tailored accordingly in different mouse 
strains. 
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4.4.  CONCLUSIONS 
In conclusion, chronic i.p. paraquat administration, using the most common sub-
lethal exposure paradigm, did not cause alterations in the spontaneous motor activity, 
oxidative stress, or changes to DA or DA turnover in either C57BL/6J or FVB mice.  
There is conflicting and contradictory reports regarding neurodegeneration induced by 
paraquat, and it is unclear whether paraquat can be used as a Parkinson’s disease model 
in mice. This study highlights the need to verify and confirm which strains of mice and 
which exposure regimens consistently produce neurotoxicity to study paraquat induced 
Parkinson’s disease models. Until a reliable model of the chronic effects of paraquat on 
the dopaminergic neurons can be agreed upon, we will be unable to move forward with 
understanding the role of paraquat exposure and Parkinson’s disease risk in humans. 
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Table 4.1. Motor Assessment Pre- and Post-treatment of 10mg/kg i.p. Paraquat Exposure Twice a Week for 3 Weeks in 
C57BL/6J and FVB Mice. 
 Saline Paraquat 
 Pre-Treatment Post-Treatmenta Pre-Treatment Post-Treatmenta 
 C57BL/6J Mice 
Total distance traveled (m) 28.3 ± 3.3 24.1 ± 12.3 29.1 ± 7.4 33.0 ± 10.0 
Speed (m/sec) 0.047 ± 0.005 0.040 ± 0.021 0.049 ± 0.012 0.043 ± 0.017 
Time spent immobile (sec) 136 ± 50 269 ± 77* 135 ± 74 260 ± 92* 
Number of line crossings 554 ± 65 473 ± 222 560 ± 151 486 ± 185 
Number of rearings 131 ± 40 133 ± 51  127 ± 43 134 ± 57 
Distance traveled from center over 10 min (m) 0.178 ± 0.006 0.177 ± 0.007 0.181 ± 0.008 0.180 ± 0.013 
 FVB Mice 
 
 Total distance traveled (m) 38.6 ± 8.9 38.5 ± 13.0 42.4 ± 7.7 28.4 ± 5.6
** 
Speed (m/sec) 0.064 ± 0.015 0.043 ± 0.022 0.071 ± 0.013 0.047 ± 0.009** 
Time spent immobile (sec) 137 ± 40 268 ± 87* 139 ± 31 218 ± 44** 
Number of line crossings 781 ± 148 479 ± 204* 811 ± 147 555 ± 100* 
Number of rearings 237 ± 37 185 ± 112 190 ± 47 134 ± 20* 
Distance traveled from center over 10 min (m) 0.152 ± 0.016 0.178 ± 0.009* 0.160 ± 0.007 0.174 ± 0.008* 
aSignificant difference between pre- and post-treatment; *p < 0.05, **p < 0.005. 
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Table 4.2. Motor Assessment Pre- and Post-treatment of 10mg/kg i.p. Paraquat Exposure Twice a Week for 4 Weeks in 
C57BL/6J and FVB Mice. 
 Saline Paraquatb 
 Pre-Treatment Post-Treatmenta Pre-Treatment Post-Treatmenta 
 C57BL/6J Mice 
Total distance traveled (m) 30.4 ± 7.6 20.4 ± 5.5** 27.0 ± 5.4 18.0 ± 4.9** 
Speed (m/sec) 0.051 ± 0.013 0.034 ± 0.009** 0.045 ± 0.009 0.030 ± 0.008** 
Time spent immobile (sec) 124 ± 66 191 ± 85 131 ± 47 241 ± 77** 
Number of line crossings 592 ± 129 457 ± 102* 528 ± 117 422 ± 120* 
Number of rearings 139 ± 45 60.3 ± 15.7* 155 ± 72 123 ± 104 
Distance traveled from center over 10 min (m) 0.172 ± 0.014 0.166 ± 0.008 0.172 ± 0.008 0.174 ± 0.018 
 FVB Mice 
 
 
 
Total distance traveled (m) 23.2 ± 11.9 24.1 ± 7.2 32.0 ± 6.6 24.9 ± 3.8 
Speed (m/sec) 0.039 ± 0.019 0.040 ± 0.012 0.053 ± 0.011 0.041 ± 0.006 
Time spent immobile (sec) 274 ± 74 235 ± 25 191 ± 32† 241 ± 40 
Number of line crossings 458 ± 242 502 ± 127 615 ± 103 507 ± 75 
Number of rearings 141 ± 62 108 ± 48 184 ± 53 148 ± 44 
Distance traveled from center over 10 min (m) 0.169 ± 0.013 0.163 ± 0.008 0.171 ± 0.007 0.159 ± 0.015 
aSignificant difference between pre- and post-treatment; *p < 0.05, **p < 0.005 
bSignificant difference between saline and paraquat treatment; †p < 0.05 
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4.1. 
 
 
 
Figure 4.1. Striatal Oxidative Stress in C57BL/6J and FVB Mice 
Administered Either Saline or Paraquat for 3 Weeks. Saline or paraquat was 
administered i.p. at 10 mg/kg twice a week for 3 weeks. Brains were collected 1 
week following the final dose and protein carbonylation was assessed by 
measuring the levels of carbonyl groups using the OxyBlot protein oxidataion 
detection kit (Millipore, Billerica, MA). Protein carbonylation was quantified and 
are shown as mean area ± SEM. 
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4.2a        4.2b 
	    
            
Figure 4.2. Striatal DA (4.2a) and DA Turnover (4.2b) in C57BL/6J and FVB Mice Administered Either Saline or Paraquat 
for 3 Weeks. Saline or paraquat was administered i.p. at 10 mg/kg twice a week for 3 weeks. Brains were collected 1 week following 
the final dose and evaluated using electrochemical RP-HPLC detection for concentrations of DA, HVA, and DOPAC. DA 
concentrations are shown in µg/g brain tissue as mean ± s.d. (4.2a) and DA turnover (4.2b) is presented as a ratio of [DOPAC + 
HVA]/DA. Significant difference within a mouse strain between treatment groups; ap < 0.05 
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4.3. 
 
 
 
Figure 4.3. Striatal Oxidative Stress in C57BL/6J and FVB Mice 
Administered Either Saline or Paraquat for 4 Weeks. Saline or paraquat was 
administered i.p. at 10 mg/kg twice a week for 4 weeks. Brains were collected 1 
week following the final dose and protein carbonylation was assessed by 
measuring the levels of carbonyl groups using the OxyBlot protein oxidataion 
detection kit (Millipore, Billerica, MA). Protein carbonylation was quantified and 
are shown as mean area ± SEM. 
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4.4a        4.4b 
 
        
Figure 4.4. Striatal DA (4.4a) and DA Turnover (4.4b) in C57BL/6J and FVB Mice Administered Either Saline or Paraquat 
for 4 Weeks. Saline or paraquat was administered i.p. at 10 mg/kg twice a week for 4 weeks. Brains were collected 1 week following 
the final dose and evaluated using electrochemical RP-HPLC detection for concentrations of DA, HVA, and DOPAC. DA 
concentrations are shown in µg/g brain tissue as mean ± s.d. (4.4a) and DA turnover (4.4b) is presented as a ratio of [DOPAC + 
HVA]/DA. 
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CHAPTER 5 
 
 
 
SUMMARY AND FUTURE DIRECTIONS 
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The central goal of my research was to evaluate P-gp transport of pesticides 
associated with Parkinson’s disease to gain knowledge regarding the contribution of P-gp 
in Parkinson’s disease risk. To accomplish this goal, I utilized a variety of models that 
allowed me to determine if these pesticides are substrates or inhibitors of P-gp, and to 
evaluate the use of chronic paraquat treatment in mice as a reproducible model of 
Parkinson’s disease. These experiments were pivotal to evaluating the significance of 
pesticide brain distribution, P-gp transport of pesticides, and potential Parkinson’s disease 
risk. Results obtained from this research will be vital in understanding mechanisms of 
pesticide transport at the BBB and accumulation in the CNS. Understanding how P-gp 
transport is important in p[pesticide disposition will allow us to move closer to better 
diagnostic tools, or preventative mechanism for Parkinson’s disease.  
Genetic variation in the ABCB1 gene results in altered P-gp function and 
expression. Several epidemiological studies have described an association between 
ABCB1 pharmacogenetics and susceptibility to Parkinson’s disease (Bartels et al., 2008a; 
Drozdzik et al., 2003; Dutheil et al., 2010; Furuno et al., 2002; Le Couteur et al., 2001; 
Lee et al., 2004; Lee and Bendayan, 2004; Tan et al., 2005; Tan et al., 2004; Vautier and 
Fernandez, 2009; Westerlund et al., 2009; Westerlund et al., 2008). One possible 
mechanism to support this association is that ABCB1 genetic variation decreases P-gp 
activity at the blood-brain-barrier, leading to increased brain accumulation of 
neurotoxicants and an increased incidence of Parkinson’s disease. Therefore, the goal of 
this research was to evaluate the association of ABCB1 with Parkinson’s disease by 
evaluating the pesticides paraquat, rotenone, maneb, endosulfan, dieldrin, and diazinon as 
potential P-gp substrates. If P-gp transports pesticides at the BBB and is responsible for 
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maintaining low pesticide brain distribution, then a decrease in P-gp activity due to 
genetic variation in ABCB1 could significantly increase the pesticide brain concentrations 
and potential Parkinson’s disease risk. Identifying which pesticides are P-gp substrates 
provides insight into the relationship between ABCB1 and Parkinson’s disease. 
The most frequently associated pesticide with Parkinson’s disease risk is the 
herbicide paraquat. In Specific Aim 1, I evaluated the P-gp-mediated transport of 
paraquat using a combination of in vitro and in vivo models in which I determined that 
paraquat is neither a substrate nor an inhibitor of P-gp. Paraquat was screened as a 
substrate for P-gp in three in vitro experimental models: ATPase activity, xenobiotic-
induced cytotoxicity, and transepithelial permeability. Paraquat did not stimulate the P-gp 
mediated hydrolysis of ATP in P-gp expressing membranes, P-gp expression did not alter 
sensitivity to paraquat-induced cytotoxicity in cells, and there was no directional 
transepithelial transport of paraquat mediated by P-gp. In addition, paraquat did not 
inhibit R123 efflux in P-gp-expressing cells and therefore is not a P-gp inhibitor. This 
work indicates that paraquat is not a P-gp substrate or inhibitor.  
  In addition to the in vitro models, paraquat was evaluated as a P-gp substrate in 
vivo in Specific Aim 1. While there were subtle differences in the systemic 
pharmacokinetic parameters between wild-type and knock-out mice, we did not observe 
differences in brain-to-plasma partitioning or total brain accumulation of paraquat 
between FVB wild-type and mdr1a(-/-)/1b(-/-) mice, which was the most important 
indicator that paraquat is not a P-gp substrate. Therapeutic agents that are P-gp substrates 
such as amprenavir, ivermectin or vinblastine, display approximately 20-80-fold increase 
in brain accumulation in knock-out mice relative to wild-type mice due to loss of P-gp 
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activity at the blood-brain-barrier (Polli et al., 1999; Schinkel et al., 1994; van Asperen et 
al., 1996). Alterations in drug-metabolizing enzymes and drug transporters occur in 
mdr1a(-/-)/1b(-/-) mice and may account for the differences in paraquat pharmacokinetics I 
observed (Schuetz et al., 2000). However, the lack of differences in brain concentrations 
between wild-type and knockout mice imply that P-gp is not involved in paraquat efflux 
in the BBB. Therefore, our in vivo models confirms our in vitro results that paraquat is 
not a P-gp substrate.  My research with paraquat in Specific Aim 1 was the first 
comprehensive study designed to measure P-gp transport of paraquat in a variety of in 
vitro and in vivo  models.  
We found in Specific Aim 1 that paraquat, the pesticide most commonly 
associated with Parkinson’s disease, was not a substrate or inhibitor of P-gp, and thus the 
association between genetic variation in ABCB1 and Parkinson’s disease risk was not due 
to altered paraquat exposure. However, exposure to other pesticides has also been linked 
with an increased risk of developing Parkinson’s disease. It was important to further 
investigate the relationship between ABCB1 and Parkinson’s disease by evaluating other 
Parkinson’s disease associated pesticides as P-gp substrates. Thus, in Specific Aim 2, I 
systematically evaluated the P-gp mediated transport of diazinon, dieldrin, endosulfan, 
maneb, MPP+, rotenone, or ivermectin using a combination of in vitro models. All of the 
above mentioned pesticides besides ivermectin have been associated with Parkinson’s 
disease risk. I observed no role for P-gp in the disposition of diazinon, dieldrin, 
endosulfan, maneb, and MPP+, however I observed that rotenone maybe a substrate of P-
gp. Rotenone stimulated ATPase activity with a lower Km than the known P-gp substrate, 
verapamil, suggesting that rotenone binds tightly to P-gp. These data demonstrate the first 
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piece of evidence to provide a mechanism for the causal relationship between P-gp and 
Parkinson’s disease, possibly due to P-gp-mediated disposition of the pesticide rotenone. 
To summarize the implications of the findings from Specific Aim 2, I discovered 
that the pesticide rotenone is a substrate of P-gp, which provides a possible explanation 
for the epidemiological evidence that has linked genetic variation in ABCB1 with 
Parkinson’s disease risk. In order to move forward with this exciting observation further 
research regarding the relationship between P-gp and rotenone is needed. The next step is 
to utilize the models described herein to further confirm rotenone as a P-gp substrate to 
validate the hypothesis that rotenone is the environmental neurotoxicant that links genetic 
variation in ABCB1 to Parkinson’s disease. Rotenone transepithelial transport in LLC-
MDR1-WT and LLC-vector cells as well as an in vivo evaluation in FVB wild-type and            
mdr1a(-/-)/1b(-/-)  mice should be utilized to more completely understand P-gp transport of 
rotenone at the BBB.  
A future direction of this research is to evaluate the pesticide rotenone using LLC-
MDR1-variant cells. The functional ABCB1 SNPs 1236C>T, 2677G>T/A, and 3435C>T 
have all been shown to alter P-gp expression or function, and have been associated with 
an altered risk of developing Parkinson’s disease. Transepithelial transport, intracellular 
accumulation, and cytotoxic sensitivity assays using recombinant LLC-PK1 cells lines 
expressing either wild-type or a variant ABCB1 will investigate if genetic variation in 
ABCB1 results in altered P-gp transport of rotenone.  
A current controversial topic is the reproducibility of the mouse model of 
Parkinson’s disease induced by chronic paraquat exposure.  Several groups have reported 
a reduction in the number of TH+ neurons and loss of DA, DOPAC, and HVA in the 
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SNpc following i.p. administered paraquat to C57BL/6J mice (Brown et al., 2006; Jiao et 
al., 2012; Li et al., 2005b; McCormack et al., 2006; Prasad et al., 2009; Ren et al., 2009; 
Shepherd et al., 2006). Motor behavior has been reported to be affected by chronic 
paraquat administration (Brooks et al., 1999; Li et al., 2005b; Ren et al., 2009). However, 
there is growing evidence that suggests chronic exposure to paraquat in rodents does not 
result in Parkinson’s disease phenotypes. Locomotor activity as well as the 
concentrations of DA, HVA, and DOPAC, as well as DA turnover in the striatum of 
C57BL/6J mice have been reported to be either unaffected or only marginally affected 
following paraquat exposure (Breckenridge et al., 2013; McCormack et al., 2002; 
Shepherd et al., 2006; Woolley et al., 1989; Yang et al., 2007). Another important finding 
is that paraquat-induced SNpc neuron DA loss is highly dependent on genetic 
background. C57BL/6J but not Swiss-Webster mice are susceptible to dopaminergic 
toxicity following chronic paraquat administration (Jiao et al., 2012). Thus, the goal of 
Specific Aim 3 was to investigate the contradictory evidence regarding the death of 
dopaminergic neurons following chronic i.p. paraquat exposure. Paraquat neurotoxicity 
was evaluated in two different mouse strains: 1) the standard mouse strain used as a 
model of paraquat-induced Parkinson’s disease, C57BL/6J mice, and 2) FVB mice, 
which have not previously been used as a model of neurotoxicant-induced Parkinson’s 
disease.  
In my evaluation of chronic paraquat exposure in mice and validation of the 
paraquat model of Parkinson’s disease I replicated the most common sub-lethal exposure 
paradigm. Following administration of 10mg/kg paraquat i.p. either twice a week for 3 
weeks, or for 4 weeks,   I observed no differences in spontaneous locomotor activity, 
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oxidative stress,  or DA concentration between saline and paraquat treatment in either 
C57BL/6J or FVB mice. The results gained from my research regarding the effect of 
chronic i.p. paraquat administration in mice are supported by other reports of a lack of 
change in DA levels or DA turnover in the striatum in C57BL/6J mice (Breckenridge et 
al., 2013; McCormack et al., 2002; Woolley et al., 1989). Combining our observations 
with previous evidence it is clear that paraquat-induced dopaminergic dysfunction is 
highly dependent on mouse strain. Thus, administering paraquat chronically to induce 
motor dysfunction, oxidative stress and dopamine loss in the striatum of C57BL/6J mice 
is not possible using the regimen that is currently described; it remains uncertain whether 
that paraquat can induce Parkinson’s disease in mice. Future work in this area should 
focus on developing a consistently reproducible mouse model of paraquat-induced 
Parkinson’s disease in which the route of administration, dosing regimen, and strain of 
mouse are standardized and reproducible.  In order to better understand Parkinson’s 
disease and paraquat exposure in humans it is vital that this model be further validated 
and reported. 
In addition to Parkinson’s disease, ABCB1 has been linked to susceptibility to 
other diseases such as childhood acute lymphoblastic leukemia, renal cancer, multiple 
myeloma, irritable bowl syndrome, Alzheimer’s disease, progressive supranuclear palsy, 
and multiple system atrophy (Bartels et al., 2008b; Blokzijl et al., 2007; Jamroziak et al., 
2004; Kuhnke et al., 2007; Maggini et al., 2008; Semsei et al., 2008; Siegsmund et al., 
2002; Urayama et al., 2007; van Assema et al., 2012). The results from these future 
studies with recombinant ABCB1 variant cells will likely have application in these 
	  
	  114	  
diseases as well. Understanding the complex interplay between genes and environmental 
exposure may lead to novel methods of disease detection, prevention, and treatment. 
In conclusion, pesticides threaten the safety of drinking water in rural 
communities, impose a risk to applicators and manufacturers in occupational settings and 
have been highly linked to the development of Parkinson’s disease. It is clear from my 
research that while the pesticide paraquat is not a P-gp substrate, further validation of 
paraquat as a Parkinsonian neurotoxicant in animals models is desperately needed before 
we can further link paraquat exposure to Parkinson’s disease.  The information gained 
from this research regarding the pesticide rotenone as a P-gp substrate could result in new 
standards and regulatory policies for drinking water in rural communities. People residing 
in rural communities should be evaluated for their ABCB1 genotype and advised 
accordingly for the safety of consumption of well water. In addition, the Federal 
Insecticide, Fungicide, and Rodenticide Act (FIFRA) under the sections “Restricted-Use 
Classification and Certification of Applicators” and “Worker Protection Standard for 
Agricultural Pesticides”, suggest that the use of some pesticides be limited if they cause 
adverse effects even when used as directed. The FIFRA may be improved by 
incorporating data gained from this research to require that people working with rotenone 
be assessed for individual risk based on their ABCB1 genotype. This research is unique 
because it linked together pharmacokinetics and toxicology to evaluate the result of 
pesticide exposure on human health. This research has the potential to be applied 
translationally in the promotion of individualized risk assessment in people who are 
exposed to disease-causing toxicants in their environment and could impact large 
numbers of people worldwide. 
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